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treat	 each	 of	 these	 disorders,	 but	 do	 so	 individually	 even	 though	 they	 are	manifestations	 of	
common	 pathologies.	 	 In	 other	 words,	 a	 patient	 will	 be	 prescribed	 different	 medications	 for	






molecules	 (D-tagatose	 and	 trans-polydatin)	 that	 have	 shown	 benefits	 in	 treating	 individual	





safety,	 an	 IND	 was	 granted	 to	 evaluate	 the	 safety	 and	 efficacy	 of	 D-tagatose	 in	 treating	
hyperglycemia	in	T2DM.			Phase	2	and	3	global	clinical	trials	were	completed	showing	D-tagatose	
to	be	highly	 safe	and	moderately	effective.	 	The	decision	was	made	 to	 search	 for	a	molecular	
complement	to	D-tagatose	that	could	more	completely	treat	T2DM.	
Dihydromyricetin	 and	 trans-polydatin	 were	 identified	 through	 literature	 searches	 as	
potentially	 synergistic	 with	 D-tagatose.	 	 Both	 molecules	 were	 tested	 in	 combination	 with	 D-
tagatose	for	their	ability	to	prevent	diet-induced	elevations	in	cholesterol	markers	in	ApoE-/-	mice.	
Dihydromyricetin	 appeared	 to	 be	 additively	 effective	 with	 D-tagatose	 for	 lipids,	 but	 trans-
polydatin	showed	synergy	in	prevention	of	cholesterol	elevations	as	results	were	greater	for	the	








concert	 compared	 to	 trans-polydatin	 alone.	 	 The	 indication	 sought	 for	 the	 IND	 is	 Prader-Willi	
Syndrome	(PWS)	due	to	the	added	potential	of	D-tagatose	to	impart	satiety	and	reduce	weight	
gain.		PWS	is	a	genetic	disorder	in	which	patients	develop	insatiable	hunger	that	leads	to	obesity	
and	often	diabetes	while	 in	 childhood.	 	 There	 is	 currently	only	 symptomatic	 treatment	of	 the	
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Plasma	 [14C]-Fructose	 Measurement	 Following	 Oral	 Administration	 of	 a	 Bolus	
[14C]-Fructose/Glucose	Preparation	......................................................................................12	
Effect	of	D-tagatose	on	Plasma	[14C]-Fructose	Absorption	Following	Oral	Administration	of	














































































































by	 reading	 this	 document	 straight	 through,	 feeling	 free	 to	 skip	 over	 repetitive	 portions	 of	
published	articles	that	may	be	present	in	the	introduction	sections	of	each	chapter.		The	tables,	

















approval	as	an	act	of	safety	 to	 the	public,	not	 to	do	the	 job	of	 the	drug	development	team	 in	
suggesting	 disease	 states	 to	 target,	 animal	models	 to	 pursue,	 or	 even	 a	marker	 of	 efficacy	 to	
evaluate	for	a	treatment	that	has	shown	activity,	although	they	will	provide	some	help	with	this	
when	 they	 can.	 	Ultimately,	 it	 is	 up	 to	 the	development	 team	 to	 scour	 the	 literature,	 consult	
experts	 and	 specialists	 at	 various	 points,	 conduct	 the	 necessary	 safety	 and	 efficacy	 studies,	
comply	with	 drug	 quality	 regulations	 through	 Good	Manufacturing	 Practices	 (GMP)	 tests	 and	
documentation	(GDP),	choose	a	disease	with	the	best	chance	of	surviving	the	approval	process,	
taking	a	drug	back	 into	animal	studies	after	clinical	 trials	when	appropriate	 to	 learn	more	and	
tweak,	and	then	take	back	into	the	clinic	with	more	information	and	a	better	development	plan.	
This	dissertation	presents	the	path	of	such	a	process	for	BSN272,	the	combination	of	D-tagatose	































be	 approved	 by	 the	 Investigational	 Review	 Board	 (IRB).	 	 In	 the	 90’s	 this	 was	 common	 and	
numerous	small	scale	human	trials	were	conducted	with	D-tagatose	to	assess	 its	safe	use	as	a	
food	additive4,8–14	for	which	is	was	given	Generally	Recognized	as	Safe	(GRAS)	status	by	the	FDA2,15	
and	many	 other	 foreign	 regulatory	 bodies.	 	 This	 led	 to	 small	 clinical	 trials	 to	 determine	 if	 D-
tagatose	could	be	efficacious	as	an	anti-hyperglycemic	medication	in	T2DM	patients.5–7,16,17	In	the	








and	 efficacy.	 	 Dr.	 Lodder	was	 recruited	 as	 the	 PI	 to	 plan	 and	 conduct	 this	 Phase	 III	 trial	 (and	
subsequent	 Phase	 II	 trial)	 due	 to	 his	 knowledge	 of	 the	 regulatory	 arena	 of	 pharmaceutical	
development.	
Both	of	these	studies	(Phase	III	and	Phase	II)	were	completed	just	prior	to	my	joining	the	lab.		I	
had	 the	 opportunity	 to	 become	 familiar	with	D-tagatose,	 T2DM,	 and	 regulation	 as	 I	 co-wrote	
these	 papers	 for	 academic	 submission.	 	 The	 Phase	 III	 article	 published	 in	 the	 Journal	 of	
Endocrinology	Diabetes	&	Obesity	is	presented	in	Appendix	A	(with	formatting	changes	to	match	
this	document).		In	this	study	15	g	of	D-tagatose	administered	three	times	a	day	proved	safe	and	
efficacious	 for	 the	 treatment	 of	 hyperglycemia	 in	 the	 subjects	 involved	 as	 seen	 by	 significant	
lowering	 of	 HbA1c	 values	 at	 all	 post-baseline	 time-points	 in	 the	 treatment	 group.	 	 Of	 some	













of	pancreatic	beta	cell	 function,	that	affects	more	than	400	million	people	globally.19	 	 It	 is	also	
known	as	non-insulin	dependent	diabetes	mellitus	(NIDDM)	to	distinguish	the	disease	from	Type	
1	Diabetes	Mellitus	or	insulin	dependent	diabetes	mellitus.		In	the	latter	disease,	the	pancreas	of	






D-tagatose	 is	 an	 example	 of	 an	 oral	 antihyperglycemic	 agent	 and	 for	 the	 remainder	 of	 this
manuscript	any	reference	to	diabetes	is	regarding	the	type	2	variety.








the	 inability	of	 the	body	 to	maintain	 it	 at	a	normal	 level	with	 insulin.	 	 The	2	hallmarks	of	 this	
disruption	is	progressive	loss	of	pancreatic	beta	cell	function	in	releasing	insulin	and	progressive	
resistance	to	insulin	by	peripheral	tissues.21	















the	 hemoglobin	 is	 in.	 	 Because	 the	 lifespan	 of	 a	 red	 blood	 cell	 is	 around	 3-4	 months,	 the	













still	 at	 higher	 risk	 than	 healthy	 individuals	 for	 developing	 heart	 disease	 or	 having	 a	 stroke.	
Treatment	 at	 this	 stage	 is	 limited	 to	 changes	 in	 lifestyle	 including	 diet	 and	 exercise,	 with	
pharmaceutical	treatment	limited	to	the	comorbidities	that	may	be	present	such	as	high	blood	
pressure	 or	 hyperlipidemia.23	 	 If	 a	 patient	 progresses	 to	 T2DM	 usually	 one	 or	 two	 oral	 anti-
hyperglycemic	drugs	are	added.24	 	 In	2012,	according	the	American	Diabetes	Association,	$245	
billion	 was	 spent	 on	 patients	 that	 had	 been	 diagnosed	 with	 T2DM,	 which	 didn’t	 include	 an	
estimated	8	million	people	that	were	undiagnosed.25	
There	has	been	a	large	introduction	of	new	medications	into	the	market	over	the	last	decade	for	
the	 treatment	 of	 T2DM,	 however,	 it	 is	 estimated	 that	 over	 60%	of	 patients	 continue	 to	 have	
HbA1c	 levels	 above	 target	 goals	 even	 with	 aggressive	 therapies.24	 	 A	 recent	 review	 of	 140	
controlled	trials	and	26	observational	studies	concluded	that	the	long-term	benefits	and	harms	
for	 currently	available	 treatments	 remains	unclear.26	 	 It	 is	 clear	 that	 there	 remains	a	need	 for	




it	 useful	 as	 an	 additive	 to	 current	 therapies	 and	 possibly	 synergistic	 with	 them,	 produce	 no	
hypoglycemia,	weight	 gain,	 or	 other	 dose	 limiting	 side	 effect	 encouraging	 its	 use	 early	 in	 the	








D-tagatose-1-phopshate	 by	 fructokinase.	 	 This	 metabolite	 (D-tagatose-1-phosphate)	 has	 been






meal,	 causes	 an	 increase	 in	 fructose-1-phosphate	 through	 competitive	 inhibition	 of	 the	 same	
metabolizing	 enzymes	 for	 both	 carbohydrates.6	 Furthermore,	 cleavage	 of	 D-tagatose-1-P	 by	
aldolase	occurs	at	about	half	the	rate	as	it	does	for	the	same	actions	on	fructose-1-P.		This	again	






Notwithstanding	 the	experiments	 that	 led	 to	 the	proposed	mechanism	of	action	 in	Figure	1.0,	
there	was	the	possibility	that	the	main	driver	of	reductions	in	blood	sugar	with	administration	of	
D-tagatose	was	actually	due	 to	 its	 inhibition	of	absorption	of	other	carbohydrates	when	given




of	 fructose,	 as	 the	 method	 of	 administration	 in	 practice	 was	 likely	 to	 be	 with	 meals	 often
containing	high	amounts	of	fructose.
In	Chapter	2	a	study	is	presented	in	which	radiolabeled	[14C]-fructose	was	administered	with	and	
































	normalization	 conversion	 factor.35	 	 Furthermore,	 the	 reduction	 did	 not	 appear	 to	 be	 dose	













other	 avenues	 for	 the	 drug	 that	 we	 could	 pursue.	 	 In	 addition	 to	 glucose	 and	 HbA1c	






It	 was	 hypothesized	 that	 the	 addition	 of	 an	 agent	 to	 D-tagatose	 with	 the	 ability	 to	 lower	 or	
maintain	triglyceride	levels	could	produce	a	product	able	to	treat	a	myriad	of	developments	of	
T2DM;	 hyperglycemia,	 hyperlipidemia,	 hypercholesterolemia,	 and	 the	 development	 of	
atherosclerosis.		Traditionally	these	are	categorized	and	treated	separately	even	though	they	have	
common	 etiologies	 and	 with	 pathways	 that	 overlap.	 	 A	 search	 of	 the	 literature	 revealed	 2	
candidates	that	could	fulfill	this	role;	trans-polydatin	and	dihydromyricetin.	
1.4.1	BSN272	in	LDLr-/-	Mice			




myocardial	 infarction	 in	 T2DM	 patients	 is	 equal	 that	 of	 non-diabetic	 individuals	 that	 had	
previously	 had	 a	 heart	 attack.38	 	 This	was	 an	 important	 consideration	 for	D-tagatose	 because	
















III	 and	 II	 trials	 of	 D-tagatose	 in	 T2DM	 patients	 as	 secondary	 aims.	 	 The	 Phase	 III	 study	 was	
described	previously	and	 the	publication	 is	available	 in	Appendix	A.	 	 LDL	and	 total	 cholesterol	
were	slightly	but	significantly	reduced	in	the	D-tagatose	group	compared	to	placebo	from	month	
6	 on	 in	 the	 ITT	 population,	 although	 there	 was	 also	 a	 slight	 but	 significant	 reduction	 in	 HDL	
cholesterol.		Of	more	concern	was	a	somewhat	robust	elevation	in	triglycerides	in	the	D-tagatose	
group	that	became	significant	in	month	8	and	reached	its	peak	at	the	completion	of	the	study.37		
These	 results	 were	 concerning	 given	 the	 CVD	 risks,	 outlined	 above,	 in	 this	 population.		
Additionally,	the	phenotype	of	dyslipidemia	in	the	T2DM	population	favors	increased	circulation	
of	 triglyceride-rich	 lipoproteins	 (TRL),	 as	 opposed	 to	 increased	 LDL	 as	 seen	 in	 the	 general	
hyperlipidemic	 population,	 which	 have	 increased	 atherogenic	 potential.	 	 Recent	 research	 has	
shown	that	statins	fail	to	correct	these	features	present	in	diabetic	dyslipidemia,	and	the	addition	
of	niacin	or	fibrates	to	statin	therapy	show	no	benefit.44	
The	 first	 combination	 study	 with	 a	 lipid	 lowering	 therapy	 involving	 D-tagatose	 was	 with	 a	
derivative	of	trans-resveratrol	known	as	trans-polydatin	(or	polydatin).		The	studies	were	part	of	
a	 collaboration	 between	 labs	 in	 the	 pharmaceutical	 sciences	 and	 physics	 departments	 at	 the	
University	of	Kentucky.		The	initial	study	involved	administering	doses	of	D-tagatose	and	polydatin	
to	LDL-/-	mice	fed	a	high	fat,	cholesterol,	and	carbohydrate	(Western)	diet	in	a	modeling	system	























due	 to	 insufficient	group	numbers	and	 it	was	hypothesized	 that	a	greater	number	of	 subjects	
would	have	led	to	significant	results	based	on	the	trends	seen.46	
7








derived	 from	was	 administered	 to	 rats	 reduced	 total	 cholesterol	 and	 triglycerides,	 as	 well	 as	
increased	HDL	cholesterol,	reported	that	a	drink	of	the	same	extract	given	to	humans	had	similar	
results.48		In	Chapter	3	a	study	is	presented	in	which	dihydromyricetin	and	D-tagatose	(BSN723T)	
were	 added	 to	 the	 food	 of	 ApoE-/-	mice	 (genetically	modified	 to	 produce	 hyperlipidemia	 and	
atherosclerosis)	 to	determine	the	ability	of	 the	combination	of	 the	two	agents	 to	prevent	diet	
induced	 increases	 in	 triglycerides,	 total	 cholesterol,	 and	 ultimately	 the	 formation	 of	
atherosclerotic	plaques.			








BSN723T	 did	 no	 better	 at	 reducing	 serum	 triglycerides	 than	D-tagatose	 in	 the	 ApoE-/-	 8-week	
study.	Furthermore,	an	unpublished	study	using	Syrian	golden	hamsters	showed	that	polydatin	
monotherapy	 greatly	 increased	 triglyceride	 levels.	 	 However,	 BSN272	 dramatically	 reduced	
triglyceride	levels	despite	a	lack	of	activity	towards	this	measurement	for	D-tagatose	or	polydatin	
alone	(unpublished	study	reviewed	in	the	Introduction	section	of	Chapter	4).	The	trend	toward	





fed	diets	 containing	BSN272	 for	16	weeks	and	measured	 for	 serum	 levels	of	 total	 cholesterol,	
triglycerides,	 and	 the	 development	 of	 atherosclerosis	 in	 the	 aortic	 arch.	 	 BSN272	was	 able	 to	







this	 study	which	 found	 the	only	adverse	 test	article-related	 finding	 to	be	chronic	active	pelvic	







a	potential	 indication	 for	 future	 clinical	 trials	 as	patients	with	 the	disease	develop	T2DM	very	
young	and	at	an	extremely	high	 rate.	 	 I	have	written	 the	 IND	which	 is	 in	 the	process	of	being	











other	 lower	 energy	 bulk	 sweeteners,	 measured	 by	 a	 68%	 conversion	 of	 14C	 radiolabeled	 D-
tagatose	 oral	 dose	 to	 14CO2,	 while	maintaining	 a	 lower	 net	 energy	 content	 than	 sucrose.1	 	 A	













on	 absorption	 or	 effects	 on	 blood	 glucose	 of	 D-tagatose	when	 co-administered	with	 another	
carbohydrate,	as	it	would	be	in	practice	when	consumed	with	a	meal.	Previous	works	in	multiple	
labs	 have	 explored	 the	 phenomenon	 that	 the	 absorption	 of	 carbohydrates	 vary	 when	
administered	alone	or	in	conjunction	with	other	carbohydrates.53		Truswell	et	al.	determined	that	
fructose	exhibits	a	saturable	effect	upon	oral	absorption.		When	given	50	g	orally	of	pure	fructose,	
58	 of	 100	 subjects	 were	 classified	 as	 poor	 absorbers	 while	 only	 19	 of	 these	 previous	 poor	
absorbers	were	unable	to	properly	absorb	25	g	of	pure	fructose.		Interestingly,	when	glucose	was	
given	with	50	g	of	fructose,	the	number	of	poor	absorbers	of	fructose	was	cut	in	half.34		This	study	
was	 confirmed	 years	 later	 in	 a	 rat	model	 in	which	 researchers	 at	 the	 University	 of	 California	


































School	 Of	 Medicine	 and	 subsequently	 confirmed	 at	 the	 Research	 Department	 of	 Nutrition,	








tagatose	 achieves	 its	 effects,	 and	how	 it	 interacts	with	 other	 components	 of	 the	human	diet,	
especially	other	carbohydrates.53	
Previous	work	 in	multiple	 labs	has	explored	the	variable	absorption	of	different	carbohydrates	
when	 administered	 alone,	 or	 in	 conjunction	 with	 other	 carbohydrates.	 Truswell	 et	 al.34	
determined	that	fructose	exhibits	a	saturable	effect	upon	oral	absorption.	When	given	50	g	orally	
of	pure	 fructose,	58	of	100	 subjects	were	 classified	as	poor	absorbers,	while	only	19	of	 these	
previous	poor	absorbers	were	unable	to	properly	absorb	25	g	of	pure	fructose.	Interestingly,	when	
glucose	was	given	with	50	g	of	fructose,	the	number	of	poor	absorbers	of	fructose	was	cut	in	half.	
This	 study	was	confirmed	years	 later	 in	a	 rat	model,	 in	which	 researchers	at	 the	University	of	







new	 information	D-tagatose	 consumption	with	 fructose	 through	 administration	 of	 14C	 labeled	
fructose	 and	 D-tagatose	 concomitantly,	 and	 comparing	 the	 radioactivity	 present	 in	 plasma	
11
	samples	collected	at	various	time	points	to	that	of	fructose	monotherapy	in	a	rat	model.	We	first	
completed	 a	 pilot	 study	 using	 [14C]-fructose	 with	 glucose,	 to	 establish	 the	 viability	 of	 our	
procedure	to	measure	changes	in	carbohydrate	absorption,	and	subsequent	plasma	levels,	and	to	
derive	 the	 amount	 of	 radioactivity	 that	 would	 be	 needed	 in	 the	 fructose	 batch	 to	 obtain	
interpretable	scintillation	count	data.	From	the	results	of	this	initial	study,	we	aimed	to	establish	
the	effect	that	a	graduated	change	in	concentration	of	D-tagatose	would	have	on	absorption	of	2	







































































14C  Fructose in  Plasma











Fructose 250 plus Glucose
Fructose 83.5

































Bonferroni's Multiple Comparison Test Mean Diff. Significant? P < 0.05? Summary
F 250 vs F 250 + G 1325 Yes ***























the	 study.	 	 Figure	 2.3A	 represents	 this	 by	 overlapping	 the	 graphs	 of	 AUC	 from	 the	 different	
treatment	arms.		Figure	2.3B	shows	that	600,	2000,	and	6000	mg	of	D-tagatose	per	kg	of	body	
weight	decreased	the	AUC	of	fructose	absorption	by	71	(1%	decrease),	1801	(26%	decrease),	and	















Fructose 250  plus Glucose
Fructose 83.5













































Fruc 250  & glucose
Fruc 83.5























The	 study	 at	 hand	 consisted	of	 two	phases.	 	 The	 aim	of	 the	pilot	 portion	was	 twofold:	 (1)	 to	
determine	the	 level	of	 radioactivity	 in	 fructose	that	needed	to	be	present	 in	order	 to	produce	
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Vehicle 600 mg/kg Tagatose 2000 mg/kg Tagatose 6000 mg/kg Tagatose







































Bonferroni's Multiple Comparison Test Mean Diff. Significant? P < 0.05? Summary
Vehicle vs 600 mg/kg Tagatose 71 No ns
Vehicle vs 2000 mg/kg Tagatose 1801 Yes ***






















that	 the	absorbed	 fructose	had	on	glycemia,	or	more	 importantly,	 the	ability	of	D-tagatose	 to	
blunt	the	glycemic	effect	of	fructose	was	established.	
The	pilot	 study	determined	 that	a	 radioactivity	 level	of	250	uCi/g	of	 fructose	was	sufficient	 to	
accurately	measure	the	amount	of	fructose	in	the	plasma	after	oral	administration	via	oral	gavage.		
The	amount	of	fructose	present	in	plasma	when	administered	with	equal	amounts	of	glucose	was	
reduced	compared	 to	 fructose	monotherapy.	 	Additionally,	 fructose	administration	 resulted	 in	
hyperglycemia	in	all	arms	of	the	study.		Both	these	findings	appear	to	be	controversial	in	light	of	
other	literature,34,54,55	yet	there	are	multiple	reasons	this	conclusion	may	be	unwarranted.		Firstly,	
the	 pilot	 study	 wasn’t	 designed	 for	 external	 validity	 of	 previous	 studies,	 only	 to	 lay	 the	
groundwork	 for	 the	second	part	of	 the	 fructose/D-tagatose	study	 to	 follow.	 	For	 instance,	our	
study	lacked	a	sham	group	(receiving	the	catheter	but	no	active	substance).		Because	of	this,	it	is	
impossible	 to	determine	 the	effect	 that	 the	procedure	 itself	 had	on	absorption.	 	 Boudry	et	 al	
established	in	a	study	conducted	in	2007,	that	stress	induced	to	rats	can	cause	an	upregulation	of	
GLUT2	 at	 the	 apical	membrane	 of	 the	 brush	 border	 of	 the	 intestines	 and	 cause	 a	 shift	 from	



























	The	mechanism	 by	which	 D-tagatose	 is	 able	 to	 reduce	 HbA1c	 in	 diabetic	 patients	 is	 not	 fully	
established.	 The	 phase	 2	 and	 3	 clinical	 trials	 showed	 that	 with	 a	 2-week	 run-in	 period	
malabsorption	could	be	controlled	even	with	high	doses	of	D-tagatose	three	times	daily,	while	






























the	 current	 study	 the	 flavonoid	dihydromyricetin	 (DMY)	was	 added	 to	D-tagatose	 (designated	
BSN723T)	and	administered	to	a	hyperlipidemic	mouse	model.	
Dihydromyricetin	(designated	BSN723	or	DMY),	also	known	as	ampelopsin,	is	a	flavonoid	isolated	
from	 a	 number	 of	 plants,	 such	 as	Ampelopsis	 grossedentata,	 and	 used	 in	 traditional	 eastern	
medicine.	DMY	has	shown	positive	results	for	numerous	health	benefits	including	inflammation,65	





The	 pathogenesis	 of	 NAFLD	 includes	 insulin	 resistance,	 oxidative	 stress,	 mitochondrial	











give	more	weight	 to	 the	 idea	 that	 BSN272	was	 unique	 and	worth	 pursuing	 as	 a	 combination	







seen	 in	 those	 who	 are	 obese	 and	 those	 with	 type	 2	 diabetes	 and	 is	 thought	 to	 be	 a	 major	
contributor	to	the	 increased	 incidence	of	cardiovascular	disease	seen	 in	these	populations.71,72	
Such	secondary	hyperlipidemia	 is	 typically	characterized	by	elevated	 levels	of	 triglycerides	and	
low-density	 lipoprotein	 (LDL)	 cholesterol	 and	 by	 low	 levels	 of	 high-density	 lipoprotein	 (HDL)	
cholesterol.	Reduction	of	elevated	LDL	and	raising	of	HDL	have	been	major	drug	treatment	goals,	
18
and	 drugs	 have	 been	 developed	 that	 alter	 blood	 lipids	 and	 produce	 significant	 reduction	 in	
cardiovascular	events	in	patients	with	cardiovascular	disease	and	diabetes.73,74	
Elevated	serum	cholesterol	 levels	have	been	noted	 in	rodents,39	dogs,40	nonhuman	primates,41	
and	 humans42	 consuming	 a	 high-carbohydrate	 diet,	 particularly	 one	 including	 fructose	 and	
sucrose.	 Studies	 have	 provided	 evidence	 that	 fructose	 causes	 hypertriacylglycerolemia	
postprandially	both	directly	through	decreased	triglyceride	clearance,	and	indirectly	by	increasing	
liver	re-esterification	of	fatty	acids.75	Low-density	lipoprotein	receptor	deficient	(LDLr−/−)	mice	fed	
a	 high	 sucrose	 diet	 exhibited	 elevated	 serum	 LDL	 cholesterol	 concentrations	 and	 increased	
atherosclerosis	compared	to	mice	fed	an	energy-matched	diet	enriched	in	saturated	fatty	acids.43	
D-tagatose,	a	naturally	occurring	epimer	of	 fructose,	was	originally	developed	as	a	 low-calorie











synthase.31	 It	 has	 been	 suggested	 that	 D-tagatose-1-phosphate	 can	 inhibit	 glycogen
phosphorylase	 in	 the	 same	 manner	 that	 fructose-1-phosphate	 does,6	 but	 this	 has	 not	 been
directly	shown.	By	activating	glycogen	synthase	and	possibly	inhibiting	glycogen	phosphorylase,






and	digestion	of	 sucrose	 and	other	 carbohydrates	 in	 the	 small	 intestine.	D-tagatose	has	 been
shown	in	both	animal	and	human	studies	to	have	multiple	effects	including	increase	in	satiety	and
weight	control,	a	beneficial	effect	on	abnormal	blood	lipids,	a	reduction	in	atherosclerotic	plaque














Dihydromyricetin	 (BSN723	 or	 DMY),	 also	 known	 as	 ampelopsin,	 is	 a	 flavonoid	 that	 has	 been	
isolated	from	a	number	of	plants,	including	Ampelopsis	grossedentata,	Cedrus	deodara,	Hovenia	
dulcis,	and	Erythrophleum	africanum,	that	have	been	used	in	traditional	medicine.	Many	claims	
have	been	made	 regarding	 dihydromyricetin's	 numerous	 health	 benefits	 including	 antioxidant	
properties,66	 anti-cancer,79–81	 anti-hypertensive,67	 anti-inflammatory,65	 and	 anti-atherosclerotic	




2014).84	 Recently,	 Jiang	 et	 al.	 (2014)85	 examined	 the	 effects	 of	 dihydromyricetin	 on	 oxidative	
stress	and	glucose	transport	activity	in	a	methylglyoxal	(MG)-induced	PC12	cell	line	to	explore	the	
possibility	 of	 using	 dihydromyricetin	 for	 the	 treatment	 of	 MG-induced	 diabetes-associated	
cognitive	decline.	They	found	that	DMY	protected	PC12	cells	against	MG-induced	apoptosis	and	
glycometabolic	disorders,	at	 least	 in	part	by	restraining	the	hyperactivation	of	p-AMPK	activity	
and	normalizing	 the	 translocation	of	GLUT4	 from	the	 intracellular	compartment,	 resulting	 in	a	
balance	in	glucose	uptake.	
Much	attention	has	been	focused	on	the	use	of	dihydromyricetin	in	the	treatment	of	a	variety	of	











levels	 of	 several	markers	 including	 tumor	 necrosis	 factor-alpha,	 cytokeratin-18,	 and	 fibroblast	
growth	 factor	 21.	 They	 also	 found	 that	 the	 HOM-IR	 level	 was	 decreased	 in	 dihydromyricetin	
treated	 patients,	 but	 insulin	 and	 C-peptide	 levels	 were	 not	 affected.	 Levels	 of	 low-density	
lipoprotein-cholesterol	(LDL-C)	and	apolipoprotein	B	(Apo	B)	were	also	significantly	decreased	by	
dihydromyricetin,	 but	 the	 total	 cholesterol,	 triglyceride,	 high-density	 lipoprotein-cholesterol	










through	 the	 PGC-1α	 pathway	 was	 investigated	 in	 vivo	 (in	 rats	 and	 humans)	 and	 in	 vitro	 (L6	
myotubes).	 The	 results	 were	 an	 increase	 in	 irisin	 secretion	 with	 the	 administration	 of	
dihydromyricetin.	
20
Dihydromyricetin	has	also	been	 found	to	 increase	 the	 levels	of	phosphorylated	AMP	activated	
protein	kinase	(AMPK)	and	Ulk1,	and	decrease	phosphorylated	mTOR	levels.94	The	same	group	
also	found	that	dihydromyricetin	increased	levels	of	peroxisome	proliferator-activated	receptor	













dihydromyricetin,	 on	 blood	 lipids	 and	 atherosclerosis	 in	 ApoE-/-	 knockout	 mice.	 The	 ApoE	
lipoprotein	resides	on	very	low,	intermediate,	and	high	density	lipoproteins	(VLDL,	IDL,	and	HDL,	
respectively)	and	mediates	the	removal	of	lipoproteins	from	plasma	by	acting	as	a	ligand	for	low	
density	 lipoprotein	 (LDL)	 receptors.	 Mice	 are	 normally	 resistant	 to	 the	 development	 of	
atherosclerosis,	however	inactivation	of	the	ApoE	gene	in	mice	results	in	elevated	cholesterol	and	
triglycerides	 in	 these	 mice.	 Severe	 hypercholesterolemia	 and	 the	 rapid	 development	 of	
atherosclerosis	results	when	these	mice	are	fed	a	Western	type	diet	consisting	of	high	fat,	high	
cholesterol	and	high	 sucrose.97–99	The	progression	and	histopathology	of	 lesions	 in	 this	animal	
model	show	features	similar	to	those	observed	in	humans	and	other	species,	making	these	mice	
good	 models	 for	 evaluating	 diet	 composition	 and	 potential	 drugs	 for	 their	 effect	 on	
atherosclerotic	 development.98	 We	 tested	 the	 hypothesis	 that	 BSN723T	 lowers	 serum	
triglycerides	and	cholesterol,	and	prevents	the	formation	of	atherosclerosis	in	ApoE-/-	mice	fed	a	














































0	 0	 0	 6.2%	 0	 3.1	
2	 Western	
TD.88137	
34%	 1.5	g/Kg	 0	 21%	 0	 4.5	
3	 D-tagatose
TD.140143
0%	 1.5	g/Kg	 34%	 21%	 0	 3.7	
4	 BSN723	
TD.140144	
34%	 1.5	g/Kg	 0	 21%	 1.11	g/Kg	 4.5	
5	 BSN723T	
TD.140145	
































had	shown	that	much	of	 the	chow	was	 lost	 in	 the	 litter	and	 it	was	 too	difficult	 to	weigh	 food	





from	 sucrose.	 In	 contrast,	 while	 having	 the	 highest	 carbohydrate	 caloric	 content,	 the	
carbohydrate	in	the	Standard	chow	is	from	complex	carbohydrates	found	in	grain	components,	
there	is	no	sucrose	added.	In	the	TD.140143	and	TD.140145	chows,	the	sucrose	has	been	replaced	













with	 the	aortas	attached	were	 fixed	overnight	 in	4%	paraformaldehyde	made	with	phosphate	
buffered	solution,	and	then	transferred	to	phosphate	buffered	solution	for	storage.	
Blood	Analysis	





curvature	 of	 the	 aortic	 arch	 exposed,	 and	 the	 resulting	 tissue	 pinned	 to	 a	 dark	 surface.	 For	
determining	the	area	of	the	aortic	arch,	a	3	mm	line	was	drawn	in	software	downward	from	the	
root	of	the	left	subclavian	artery.	Using	the	bottom	of	this	line	as	a	base,	the	intimal	area	of	the	






















There	 was	 no	 significant	 difference	 in	 caloric	 intake	 between	 the	 Standard	 and	 D-tagatose,	
Western	and	BSN723,	Western	and	BSN723T,	or	D-tagatose	and	BSN723T	diet	groups.	There	was	
no	significant	difference	between	the	five	groups	in	terms	of	food	consumption	by	weight	of	chow	






Oxygen	 consumption	 measurements	 for	 each	 mouse	 in	 each	 study	 may	 be	 the	 best	 way	 to	




Diet	 Grams	of	food/mouse/day	 Kcal/gram	chow	 Kcal/mouse/day	
Standard	TD.2018	 3.62	±	0.16	 3.1	 11.23	±	0.49	
Western	TD.88137	 3.50	±	0.23	 4.5	 15.77	±	1.13,	+	*	
TD.140143	(D-tagatose)	 3.15	±	0.36	 3.7	 11.65	±	1.33	
TD.140144	(BSN723)	 3.63	±	0.22	 4.5	 16.34	±	0.98,	+	*	












15,	when	 the	mice	were	 started	on	 their	 respective	D-tagatose	 containing	 chows,	 and	day	21	
when	the	mice	were	next	weighed.	The	mice	in	these	two	groups	then	gained	weight	at	a	rate	









while	 there	 was	 no	 significant	 difference	 between	 the	 weights	 of	 mice	 on	 those	 three	 diets	




Mice	 on	 the	Western	 diet	 had	 increased	 total	 adipose	 tissue	 (epidydimal	 +	 retroperitoneal	 +	
subcutaneous	adipose	tissue)	compared	to	mice	on	the	Standard	diet	(Figure	3.3).	The	addition	





g	 vs	0.47	±	0.09	g,	 respectively),	 the	difference	was	not	 statistically	 significant	 (p	 =	 0.26).	 The	























































BSN723	 and	 D-tagatose	 Lower	 Serum	 Triglycerides	 Compared	 to	 Mice	 on	 Both	 the	
Standard	and	Western	Diets	




diets	 during	 the	 course	 of	 the	 study.	 By	 day	 71,	 triglycerides	 in	 Groups	 3,	 4,	 and	 5	 were	


































Flavonoids	 are	derivatives	 of	 2-phenyl-1-benzopyran-4-1	 and	 are	present	 in	 fruits,	 vegetables,	
nuts,	 and	 seeds.	 Many	 studies	 have	 found	 an	 association	 between	 flavonoid	 intake	 and	 a	
reduction	of	risk	for	coronary	events.100–102	The	flavonoid	dihydromyricetin	is	the	major	bioactive	
compound	in	Ampelsis	grossedentata,	making	up	15-20%	(wt/wt)	of	the	total	dry	weight	of	stems	
and	 leaves.103	Many	of	 the	preliminary	studies	 touting	 the	positive	effects	of	dihydromyricetin	
have	 utilized	 plant	 extracts	 which,	 in	 addition	 to	 containing	 high	 concentrations	 of	
dihydromyricetin,	 also	 contained	complex	mixtures	of	other	 flavonoids.	Chen	et	al.68	 reported	
that	the	intragastric	administration	of	extract	from	A.	grossedentata	to	rats	reduced	serum	total	
cholesterol	 and	 triglycerides	 and	 increased	 high-density	 lipoprotein.	 In	 a	 study	 using	 human	
subjects	with	hyperlipidemia,	the	administration	of	a	drink	made	from	A.	grossedentata	for	45	
days	reduced	serum	triglycerides,	total	cholesterol,	and	plasma	lipids.48		Up	to	now	few	studies	
have	 evaluated	 the	 serum	 lipid	 altering	 and	 anti-atherosclerotic	 activities	 of	 purified	
dihydromyricetin.	
Considerable	 attention	has	been	 focused	on	 the	antioxidant	 activity	of	dihydromyricetin.104,105	
Liao	 et	 al.105	 crystallized	 dihydromyricetin	 from	 A.	 grossedentata	 and	 demonstrated	 it	 was	
effective	 at	 inhibiting	 the	 production	 of	 reactive	 oxygen	 species	 in	 treated	 cells	 thereby	
attenuating	 plasma	 lipid	 peroxidation.	 It	 also	 inhibited	 AAPH-induced	 production	 of	
malondialdehyde,	an	indicator	of	lipid	peroxidation	and	a	biomarker	for	oxidative	stress.	Evidence	







diet	 (high	 fat,	 high	 cholesterol,	 high	 sucrose	 diet).	 In	 the	 diets	 containing	 D-tagatose,	 the	 D-
tagatose	replaced	the	sucrose	in	the	Western	diet	formulation.	For	the	mice	treated	with	BSN723	
alone	 (Group	 4),	 sucrose	 was	 still	 present	 in	 the	 diet,	 BSN723	 was	 just	 added	 to	 the	 chow	








prevented	 the	 development	 of	 obesity.78	 We	 obtained	 the	 same	 result	 with	 ApoE-/-	 mice.	
Differences	in	caloric	intake	between	the	5	groups	directly	correlates	with	the	final	body	weights	










known	 to	 cause	 gastrointestinal	 upset	 when	 taken	 in	 large	 enough	 doses	 without	 a	 gradual	
increase	 in	 intake,	 which	 was	 the	 reason	 for	 the	 14-day	 run-in	 period.	While	 there	 were	 no	
outward	symptoms	of	gastrointestinal	distress	in	the	mice	placed	on	the	D-tagatose	containing	












the	 Western	 diet	 (Figure	 3.5).	 The	 livers	 of	 ApoE-/-	 mice	 are	 unable	 to	 remove	 circulating	
cholesterol	 efficiently	 and	 as	 a	 result	 these	 mice	 exhibit	 elevated	 serum	 cholesterol.	
Atherosclerotic	lesion	development	is	very	dramatic	in	ApoE-/-	mice	fed	a	Western-type	diet	and	
the	beginning	stages	of	the	disease	can	be	found	at	6	weeks.97	With	the	ApoE-/-	and	LDLr-/-	mouse	




	phenotype.43,108,110	 Replacement	 of	 sucrose	 with	 D-tagatose	 in	 a	Western	 diet	 was	 shown	 to	
decrease	 serum	 total	 cholesterol	 in	 LDLr-/-	 mice	 compared	 to	mice	 on	 the	Western	 diet	 with	
sucrose.78	 We	 obtained	 similar	 results	 with	 the	 ApoE-/-	 mice.	 Total	 cholesterol	 increased	
somewhat	 in	 the	 D-tagatose,	 BSN723,	 and	 BSN723T	 fed	 mice,	 upon	 placing	 them	 on	 their	
respective	 diets	 compared	 to	 Standard	 diet,	 but	 never	 reached	 the	 levels	 of	 the	mice	 on	 the	
Western	diet.	In	future	work	the	effect	of	BSN723	on	HDL	and	LDL	cholesterol	should	be	measured	
and	compared	to	D-tagatose.	




toward	 what	 would	 be	 considered	 normal	 levels	 (see	 negative	 control).	 D-tagatose	 alone	






One	 of	 the	 objectives	 of	 this	 study	 was	 to	 determine	 if	 the	 addition	 of	 BSN723	 to	 the	 diet	
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diet	 induced	 increases	 in	 triglycerides	 compared	 to	 positive	 control	 (sucrose/Western	 diet),	
although	D-tagatose	caused	an	 increase	 in	 triglycerides	compared	 to	negative	control	 (normal	
chow)).78	 	 In	addition,	an	unpublished	study	in	our	lab	using	Syrian	golden	hamsters	fed	a	high	
fat/carbohydrate	Western	diet	(Untreated)	showed	that	trans-polydatin	actually	led	to	increased	
triglycerides	 greater	 than	 the	 increase	 caused	 by	 Western	 Diet	 alone	 (Figure	 4.1,	 compare	
untreated	and	polydatin	columns).		In	the	same	study	BSN272	using	100	mg/kg	of	the	polydatin	
component	 was	 able	 to	 significantly	 reduce	 triglycerides	 from	 baseline	 (Figure	 4.1,	 D-
tag/polydatin	100	mg/kg	column).	
It	 should	be	noted	 that	 the	 increase	 in	 triglycerides	 from	polydatin	 in	our	 study	 is	 contrary	 to	
Arichi	et	al.,112	Du	et	al.,113	and	Xing	et	al.114	which	all	reported	a	reduction	in	TG	with	polydatin,	
which	was	partly	responsible	for	its	early	selection	for	a	combination	with	D-tagatose.		In	fact	Du	
et	 al.,113	 using	 the	 same	 Syrian	 golden	hamster	model	 as	 in	 our	 study,	 reported	 the	 ability	 of	
polydatin	 to	 significantly	 prevent	 the	 diet	 induced	 increase	 in	 TG	 established	 with	 the	 high	
fat/cholesterol	diet.		A	key	difference	between	our	studies	is	that	the	polydatin	was	initiated	with	
the	 introduction	of	 the	high	 fat/cholesterol	 diet	 in	 the	Du	 study,	meaning	 that	 the	 study	was	




































	that	 came	 just	 short	 of	 significance	 for	 lowering	 of	 TG’s	 with	 the	 algorithm	 that	 predicted	
significance	 given	 a	 larger	 sample	 size,	 and	 now	what	 appeared	 to	 be	 a	 robust	 result	 in	 diet	
induced	hyperlipidemic	hamsters	with	a	questionable	procedural	mistake.		It	was	time	to	perform	
a	 study	 with	 a	 large	 number	 of	 subjects	 over	 a	 lengthy	 period	 of	 time	 in	 the	 model	 of	
atherosclerosis	 and	 hyperlipidemia	 that	 we	 had	 had	 the	 most	 success	 with	 to	 determine	









cholesterol.	 This	 disease	 commonly	manifests	 in	 those	who	 are	 obese	 and	 those	with	 type	 2	
diabetics,	and	is	thought	to	be	a	major	contributor	to	the	increased	incidence	of	cardiovascular	
disease	seen	in	these	two	populations.71,72	Reduction	of	elevated	LDL	is	a	major	drug	treatment	





and	 humans42	 consuming	 a	 high-carbohydrate	 diet,	 particularly	 one	 including	 fructose	 and	
sucrose.	 Recent	 studies	 have	 provided	 evidence	 that	 fructose	 causes	 hyperlipidemia	
postprandially,	both	directly	through	the	synthesis	of	fatty	acids,	and	indirectly	by	increasing	liver	
re-esterification	of	 fatty	acids.75	Low-density	 lipoprotein	 receptor	deficient	 (LDLr−/−)	mice	 fed	a	
high	 sucrose	 diet	 exhibited	 elevated	 serum	 LDL	 cholesterol	 concentrations	 and	 increased	
atherosclerosis	compared	to	mice	fed	an	energy-matched	diet	enriched	in	saturated	fatty	acids.43		
D-tagatose,	a	naturally	occurring	epimer	of	 fructose,	was	originally	developed	as	a	 low-calorie	








After	 absorption	 from	 the	 intestine	and	 transport	 to	 the	 liver,	 fructokinase	phosphorylates	D-
tagatose	to	produce	D-tagatose-1-phosphate.	D-tagatose-1-phosphate	can	stimulate	glucokinase	
activity29,30	 leading	 to	 increased	phosphorylation	of	 glucose	 to	glucose-6-phosphate	 leading	 to	
further	 activation	 of	 glycogen	 synthase.31	 There	 has	 been	 speculation	 that	 D-tagatose-1-
phosphate	 can	 inhibit	 glycogen	phosphorylase	 in	 the	 same	manner	 that	 fructose-1-phosphate	
does,6	 but	 this	 has	 not	 been	 directly	 shown.	 By	 activating	 glycogen	 synthase	 and	 possibly	
inhibiting	 glycogen	 phosphorylase,	 D-tagatose-1-phosphate	 increases	 glycogen	 synthesis	 and	
inhibits	glycogen	utilization,	explaining,	at	least	in	part,	the	antihyperglycemic	effect	of	the	sugar.	













atherosclerosis	 compared	 to	 mice	 on	 the	 diet	 containing	 sucrose.78	 In	 a	 human	 clinical	 trial,	





other	 studies,	 type	 II	 diabetics	 taking	 D-tagatose	 showed	 a	 decrease	 in	 HbA1c	 and	 serum	
triglycerides.4,17	
There	is	considerable	interest	in	the	use	of	trans-resveratrol	and	its	derivatives,	including	trans-




these	extracts.	 In	addition	to	Polygonum,	polydatin	has	been	 found	 in	wines	and	grapes,119–122	
cocoa,123	 peanuts	 and	 peanut	 butter,124	 pistachios,125	 and	 almonds.126	 	 As	 a	 derivative	 of	
resveratrol,	 polydatin	 is	 believed	 to	 have	 many	 of	 the	 same	 beneficial	 effects	 but	 has	 some	
properties	that	may	make	it	more	effective	from	a	pharmacological	standpoint	than	resveratrol.	
Polydatin	is	structurally	the	same	as	resveratrol	except	that	it	has	a	glucoside	group	attached	to	
the	 C-3	 position	 in	 place	 of	 a	 hydroxyl	 group.	 This	 substitution	makes	 polydatin	more	 water	
soluble	and	possibly	more	resistant	to	enzymatic	breakdown	than	resveratrol.	It	is	also	actively	
taken	up	by	cells	via	glucose	carriers	in	the	cell	membrane	instead	of	being	passively	transported	
like	 resveratrol.127,128	 	 These	 properties	 would	 suggest	 that	 polydatin	 would	 have	 greater	
bioavailability	than	resveratrol.	
Claims	for	the	many	health	benefits	of	polydatin	abound.	A	multitude	of	studies	have	presented	
evidence	 that	 polydatin	 has	 many	 positive	 health	 effects	 including	 anti-inflammatory,129,130	
hepatoprotective,131–134	 anti-cancer,135–138	 neuroprotective,129,139–141	 and	 cardioprotective	
activities.113,114,118,142,143	 	 Pharmacological	 studies	 and	 clinical	 practice	 have	 demonstrated	 that	
polydatin	 also	 has	 protective	 effects	 against	 shock,144,145	 ischemia/reperfusion	 injury,146,147	








	angiotensin	 II,142	 reduction	of	 lipid	peroxidation	 levels,127,157	up	regulation	of	 the	expression	of	
hippocampal	 brain-derived	 neurotrophic	 factor,141	 enhanced	 insulin	 sensitivity	 in	 the	 liver	 as	
shown	by	 improved	 insulin	 receptor	 substrate	2	expression	 levels	 and	Akt	phosphorylation,151	
decreasing	 the	 content	 of	 malonydialdehyde	 (MDA),140	 promoting	 the	 activities	 of	 total	
superoxide	 dismutase	 (T-SOD),	 catalase	 and	 glutathione	 peroxidase	 (GSH-Px)	 in	 plasma,	 and	
increasing	 the	 content	 of	 glutathione	 (GSH)	 in	 myocardial	 tissue,154	 restoring	 decreased	
deacetylase	sirtuin1	activity	and	protein	expression	in	liver	tissue	following	severe	shock158	and	





by	 approximately	 18%	 and	 serum	 triglycerides	 by	 40%	 in	 rats	 consuming	 standard	 chow	
containing	a	mixture	of	corn	oil,	10%	cholesterol,	and	1%	cholic	acid.	Although	 lower	doses	of	
trans-polydatin	(50	mg/kg	body	weight)	were	ineffective	at	preventing	hyperlipidemia,	they	were	
able	 to	 prevent	 the	 accumulation	 of	 cholesterol	 and	 triglycerides	 in	 the	 liver,	 suggesting	 that	
lower	doses	may	also	be	effective	but	 to	a	much	 lesser	extent.	 In	a	 study	using	Syrian	golden	
hamsters,	polydatin	was	found	to	decrease	total	cholesterol	levels	and	total	triglyceride	levels	by	
47%	 and	 63%,	 respectively,	 compared	 to	 standard	 diet.113	 In	 another	 study	 using	 rabbits,	 the	
administration	of	polydatin	decreased	the	serum	levels	of	total	cholesterol,	triglycerides,	and	LDL.	
The	ratio	of	total	cholesterol	to	HDL	was	also	reduced.114	
Insulin,	 through	 activation	 of	 the	 Akt	 pathway	 and	 other	 metabolic	 pathways,	 is	 a	 major	
component	of	metabolic	regulation.161	Hao	et	al.	recently	found	that	polydatin	activated	the	Akt	
signaling	pathway	in	diabetic	rats,	possibly	by	phosphorylation	of	the	insulin	receptor	substrate	















mice	 good	 models	 for	 evaluating	 diet	 composition	 and	 potential	 drugs	 for	 their	 effect	 on	
atherosclerotic	 development.98	We	 tested	 the	 hypothesis	 that	 BSN272	 prevents	Western	 diet	









































0.15%	cholesterol,	 34%	 sucrose	 (TD.88137));	Group	3	 -	Western	diet	 formulated	with	BSN272	
(341g	 D-tagatose/kg	 feed	 replacing	 341g	 of	 sucrose,	 plus	 1g	 polydatin/kg	 feed,	 (TD.110527	















0	 0	 0	 0	 4%	 2.9	
Western	
TD.88137	
34%	 1.5	g/kg	 0	 0	 21%	 4.5	
BSN272	
TD.110527	
0	 1.5	g/kg	 34%	 1	g/kg	 21%	 3.7	
The	ratios	of	kilocalories	provided	by	fat,	protein,	and	carbohydrates	(fat/protein/carbohydrates)	
are	 as	 follows:	 TD.2014	 (standard	 diet)	 -	 13/20/67;	 TD.88137	 (Western	 diet)	 -	 42/15/43;	
TD.110527	 (BSN272	 diet)	 -	 52/19/29.	Most	 of	 the	 carbohydrate	 content	 of	 the	Western	 diet	











the	 left	 ventricle	 was	 punctured	 to	 obtain	 blood.	 After	 the	 right	 atrium	 was	 cut,	 mice	 were	
exsanguinated	 by	 perfusion	 through	 the	 left	 ventricle	 followed	 by	 removal	 of	 tissues	 (liver,	
kidneys,	spleen,	epididymal	fat	and	retroperitoneal	fat	(both	sides),	subcutaneous	fat	(one	side	
only)	and	aortic	tissue	from	the	heart	to	the	iliac	bifurcation).	The	livers,	kidneys,	spleens,	and	fat	






















Mice	 on	 the	 Western	 diet	 consumed	 the	 highest	 number	 of	 calories	 per	 day	 (12.75	 ±	 0.63	
Kcal/mouse/day)	followed	by	the	standard	diet	group	(11.5	±	0.87	Kcal/mouse/day)	and	then	the	










Diet	 Grams	of	food/mouse/day	 Kcal/gram	 Kcal/mouse/day	
Standard	 3.97	±	0.30	 2.9	 11.51	±	0.87	
Western	 2.83	±	0.14	 4.5	 12.75	±	0.63	






































in	 the	spleens	 from	the	mice	on	 the	BSN272	and	standard	diets	 (p	=	0.013).	These	 results	are	
consistent	with	the	results	of	Kruger	et	al.	who	found	in	a	toxicology	study	of	D-tagatose	that	the	
spleens	of	both	male	and	 female	 rats	consuming	D-tagatose	as	20%	(w/w)	of	 their	diets	were	
significantly	 larger	 than	 spleens	 from	 the	 control	 group	 that	was	not	 consuming	D-tagatose.59	

























greater	 increase	 seen	 in	 the	 Western	 diet	 mice.	 Mice	 on	 the	 BSN272	 diet	 exhibited	 lower	
cholesterol	levels	than	mice	on	the	Western	diet	at	all	time	points	through	the	course	of	the	study.	
















































diet	 promoted	obesity,	 increased	 total	 serum	 cholesterol	 and	 triglyceride	 concentrations,	 and	
markedly	 stimulated	 the	development	of	atherosclerosis	 in	ApoE-/-	mice	compared	 to	mice	on	
standard	chow	(low	fat,	 low	cholesterol,	 low	sugar).	 In	contrast,	a	diet	that	replaced	gram-for-
gram	 the	 sucrose	 in	 the	 Western	 diet	 with	 D-tagatose	 along	 with	 polydatin	 (BSN272	 diet)	
prevented	the	weight	gain	seen	with	animals	on	the	Western	diet.	
The	mice	on	the	BSN272	diet	did	not	exhibit	a	gain	in	body	weight	witnessed	in	the	Western	diet	














the	mice	were	placed	on	 their	 respective	diets.	D-tagatose	 is	 known	 to	 cause	 gastrointestinal	














of	 increased	deposition	of	 lipids.165,166	After	D-tagatose	 is	 absorbed	 into	 the	bloodstream,	 it	 is	





While	 BSN272	 fed	 mice	 exhibited	 slightly	 increased	 serum	 cholesterol	 and	 atherosclerosis	
compared	to	standard	diet	mice,	the	extent	of	these	changes	was	far	less	than	those	observed	in	




















Elevations	 in	 serum	 cholesterol	 concentrations	 were	 associated	 with	 a	 striking	 increase	 in	
atherosclerotic	 lesion	 surface	 area	 in	 mice	 fed	 the	 Western	 diet	 compared	 to	 BSN272	 and	
standard	 diet	 mice.	 The	 addition	 of	 BSN272	 to	 the	 Western	 diet	 dramatically	 reduced	 the	











demonstrating	 increasing	 efficacy	 with	 a	 longer	 study	 period.	 The	 16-week	 BSN272	 group	
triglycerides	levels	(108	±	5.76	mg/dL)	were	significantly	less	than	mice	on	the	standard	diet	(157±	
9.51	mg/dL,	p	<	0.01)	or	the	Western	diet	(175	±	14.86	mg/dL,	p	<	0.01).	These	triglyceride	results	

























The	 16-week	 BSN272	 study	 in	 ApoE-/-	 mice	 and	 the	 toxicology	 study	 of	 trans-polydatin	
represented	 the	 last	of	 the	“First-in-Human	 (FIH)-enabling”	nonclinical	 studies	 required	by	 the	
FDA.		The	task	then	turned	to	packaging	the	various	studies	and	data	associated	with	D-tagatose,	
trans-polydatin,	 and	 BSN272,	 designing	 a	 phase	 1	 first	 in	 humans	 study,	 and	 submiting	 an	
indication	 with	 which	 to	 develop	 the	 IND	 towards.	 	 In	 this	 chapter	 is	 a	 summary	 of	 the	 IND	
submission,	 a	 presentation	 of	 the	 proposed	 Phase	 1	 PK	 study	 in	 healthy	 volunteers,	 and	 a	
discussion	of	Prader-Willi	syndrome,	the	proposed	indication	for	BSN272	for	future	work.	
I	 spent	 the	 last	 8	 months	 packaging	 the	 IND	 submission.	 	 Even	 in	 a	 small	 company	 the	
recommended	size	for	an	“IND	team”	is	a	minimum	of	3-4	people	in	order	to	properly	package	
















process	of	 an	 individual	new	drug	application.	 	BSN272	was	an	unusually	 complex	 submission	
because	 it	 contained	 two	 molecules	 with	 plentiful	 studies	 conducted	 each	 as	 single	 agents,	
although	 the	 drug	 was	 treated	 as	 a	 single	 entity	 due	 to	 the	 synergistic	 nature	 in	 which	 the	




observed-adverse-effect-level	 (NOAEL).	 	 In	 addition	 to	 these	 concerns,	 as	 this	 is	 the	 first	 time	












mammalian	 models	 as	 well	 as	 a	 toxicology	 study,	 in	 this	 case	 one	 for	 D-tagatose	 and	 trans-
polydatin	each.		The	drug	substance	must	also	have	a	material	safety	data	sheet	(MSDS)	from	the	
manufacturer	and	proof	of	good	manufacturing	practices	(GLP).		Section	5.3	below	should	be	used	










Studies	 have	 shown	 that	 persons	with	 Prader-Willi	 Syndrome	 (PWS)	 are	 at	 risk	 of	 premature	
death.	PWS	 is	 the	most	commonly	known	genetic	cause	of	 life-threatening	obesity	 (estimated	
prevalence	of	1:15,000),	resulting	from	obesity-related	problems	such	as	respiratory	failure	and	
pulmonary	hypertension,	obstructive	sleep	apnea,	hypertension,	cardiovascular	disease,	and	type	
2	 diabetes	mellitus	 (T2DM).	 The	 cause	 of	 death	 in	 adults	 is	 usually	 related	 to	 failures	 of	 the	
circulatory	or	respiratory	systems.	There	is	currently	no	single	drug	available	that	can	successfully	
treat	all	of	the	symptoms	of	this	complex	disorder.	
The	 major	 medical	 concern	 for	 patients	 with	 PWS	 is	 morbid	 obesity.	 Compulsive	 eating	 and	
obsession	with	food	usually	begins	between	the	ages	of	1	and	6.	The	urge	to	eat	is	physiological	
and	 overwhelming;	 it	 is	 difficult	 to	 control	 and	 requires	 constant	 vigilance.	 Weight	 control	





pulmonary	 hypertension,	 obstructive	 sleep	 apnea,	 hypertension,	 and	 type	 2	 diabetes	mellitus	
(T2DM).167–170	A	high	 incidence	of	alterations	 in	glucose	metabolism	 including	 impaired	 fasting	
glucose,	 impaired	 glucose	 tolerance,	 and	 T2DM,	 has	 been	 observed	 in	 patients	 with	 PWS,	
particularly	after	adolescence.171	Mean	age	at	onset	of	diabetes	is	about	20.	A	prevalence	rate	of	
20-25%	for	T2DM	is	found	in	patients	with	long	standing	PWS.171,172	
Obesity	 and	diabetes	 are	well-established	 risk	 factors	 for	premature	 cardiovascular	disease.	A	
limited	 number	 of	 studies	 have	 looked	 at	 cardiovascular	 fitness	 and	 disease	markers	 in	 PWS	
patients.	Cardiovascular	risk	factors	are	evident	in	a	large	percentage	of	children	with	PWS.	de	
Lind	van	Wijngaarden	et	al.	(2010)	looked	at	the	cardiovascular	and	metabolic	risk	profile	in	85	
children	 with	 PWS.	 They	 found	 that	 infants	 and	 prepubertal	 children	 had	 at	 least	 one	
cardiovascular	risk	factor.	In	63%	of	the	infants	and	73%	of	prepubescent	children,	at	least	one	of	
the	following	factors	was	present:	elevated	systolic	or	diastolic	blood	pressure;	elevated	serum	
total	 cholesterol,	 low	 density	 lipoprotein	 cholesterol,	 triglycerides,	 or	 lipoprotein(a)	 levels;	 or	
reduced	 high	 density	 lipoprotein	 cholesterol	 levels,	 indicating	 an	 unfavorable	 cardiovascular	
profile	in	addition	to	a	high	fat%,	indicating	an	unfavorable	cardiovascular	profile.173	Patel,	et	al.	
(2007)	 assessed	 cardiac	 and	 vascular	 structure	 and	 function	 in	 nine	 PWS	 patients	 and	 found	
51
	significantly	elevated	high-sensitivity	C-reactive	protein	(hs-CRP),	hs-CRP	has	been	shown	to	be	
significantly	 elevated	 in	 patients	 dying	 suddenly	 with	 severe	 coronary	 artery	 disease,174	 and	
evidence	 of	 microcirculatory	 dysfunction	 as	 evidenced	 by	 decreased	 peak	 hyperaemic	 flow	
response.175		In	a	small	study	involving	36	adults	with	PWS	who	were	followed	for	10	years	there	




D-tagatose	 (D-lyxo-hexulose)	 is	 an	 enantiomer	 of	 D-fructose	 and	 occurs	 naturally	 in	 small	
amounts	 in	 dairy	 products.	 Heat	 treatment	 causes	 D-tagatose	 to	 form	 from	 galactose	 by	






type	2	diabetes	mellitus	 (T2DM)	without	an	 IND	by	considering	D-tagatose	as	a	 food	additive.	
These	trials	demonstrated	that	D-tagatose	did	not	raise	postprandial	blood	glucose	and	blunted	
the	 rise	 in	 blood	 glucose	 when	 taken	 with	 meals.2,3	 In	 November	 2005,	 after	 review	 of	




has	 been	 safely	 administered	 to	 humans	 up	 to	 0.64	 g/day,	 although	 some	 consumers	 have	










of	 D-tagatose-1-P	 concentration	 stimulates	 glucokinase	 activity29,30,178	 leading	 to	 an	 increased	
phosphorylation	 of	 glucose	 to	 glucose-6-P,	 which	 further	 activates	 glycogen	 synthase.31	 In	
addition,	a	literature	review	also	suggests	that	D-tagatose-1-P,	in	a	manner	similar	to	D-fructose	














atherosclerosis	 compared	 to	 mice	 on	 the	 diet	 containing	 sucrose.78	 In	 a	 human	 clinical	 trial,	









containing	 products,	 cocoa,	 peanuts,	 peanut-containing	 products,	 pistachios,	 almonds,	 and	
hops.			As	a	derivative	of	resveratrol,	polydatin	is	believed	to	have	many	of	the	same	beneficial	





transported	 like	 resveratrol.127,128	 	 These	 properties	 would	 suggest	 that	 polydatin	 may	 have	
greater	bioavailability	than	resveratrol.	
There	are	many	reported	health	benefits	of	trans-polydatin.	Numerous	studies	have	presented	
evidence	 that	 polydatin	 has	 positive	 health	 effects	 including	 anti-inflammatory,129,130	
hepatoprotective,131–134	 anti-cancer,135–138	 neuroprotective,129,139–141	 and	 activities	 deemed	





The	mechanism	for	each	of	 these	outcomes	 is	still	being	 investigated.	 	Some	of	 the	suggested	
mechanisms	from	evidence	are:	an	antioxidant,	free	radical-elimination	mechanism,153,154	protein	
kinase	 C	 activation,155,156	 NF-kappaB	 suppression,157	 inhibiting	 of	 the	 activation	 of	 renin-
angiotensin-aldosterone	 system	 which	 decreases	 the	 excretion	 of	 endothelin	 1,	 TNF-α,	 and	
angiotensin	II,142	reduction	of	lipid	peroxidation	levels,127,157	increased	expression	of	hippocampal	
brain-derived	 neurotrophic	 factor,141	 	 enhanced	 insulin	 sensitivity	 in	 the	 liver	 as	 shown	 by	
improved	insulin	receptor	substrate	2	expression	levels	and	Akt	phosphorylation,151		decreasing	
the	content	of	malonydialdehyde	(MDA),140	promoting	activities	of	total	superoxide	dismutase	(T-
SOD),	 catalase	 	 and	 glutathione	 peroxidase	 (GSH-Px)	 in	 plasma,	 increasing	 glutathione	 (GSH)	
content	in	myocardial	tissue,154	decreasing	deacetylase	sirtuin1	activity	and	protein	expression	in	





by	 three	 studies	 using	 various	 animal	 models.112–114	 Arichi	 et	 al.	 discovered	 that	 orally	





and	triglycerides	 in	the	 liver,	suggesting	that	 lower	doses	may	also	be	effective	but	to	a	 lesser	
extent.112	In	a	study	using	Syrian	golden	hamsters,	polydatin	was	decreased	total	cholesterol	(TC)	
levels	and	total	 triglyceride	 levels	by	47%	and	63%,	respectively,	when	co-administered	with	a	




other	metabolic	 pathways.161	 Hao	et	 al.	 recently	 found	 that	 trans-polydatin	 activated	 the	 Akt	
signaling	pathway	 in	 diabetic	 rats.	 	 This	was	possibly	 accomplished	by	phosphorylation	of	 the	
insulin	 receptor	 substrate	 (IRS),	 thereby	 reducing	 blood	 glucose	 levels.151	 Polydatin	 may	 also	
decrease	the	expression	of	intercellular	adhesion	molecule	1	(ICAM-1),	reducing	white	blood	cell	
adhesion,	 as	well	 as	 the	effects	of	other	 cell	 adhesion	molecules	and	 inflammatory	 cytokines.		




events	 were	 reported.182	 To	 determine	 whether	 higher	 levels	 of	 trans-polydatin	 could	 be	
administered	 to	 humans,	 Biospherics.net	 evaluated	 the	 safety	 of	 polydatin	 (batch	 number	
BIPL110714)	in	a	28-day	GLP	rat	toxicology	study	with	a	toxicokinetic	test-arm	and	established	a	
no	observed	adverse	effect	level	(NOAEL)	of	3.0	g/kg/day	(the	highest	dose	tested)	in	males	and	












tmax	 and	 Cmax	 of	 trans-polydatin	 (t-PD)	 change	 significantly	 when	 co-administered	 with	 D-
lyxohexulose	(DLH,	or	D-tagatose)	in	healthy	male	and	female	volunteers	over	a	24hour	period.	
BSN272	 is	 a	 potential	 drug	 therapy	 for	 the	 treatment	 of	 persons	with	 Prader-Willi	 Syndrome	





	approximate	 the	 24-hour	 posttreatment	 period.	 Serum	and	urine	 samples	will	 be	 assayed	 for	
trans-polydatin	 and	 the	 metabolite	 trans-resveratrol	 at	 each	 time	 point	 to	 determine	 the	
pharmacokinetic	effects	of	the	combination	BSN272	drug.	
Healthy	male	 and	 female	 volunteers,	 aged	 between	 18	 and	 30	 years	 old	will	 be	 recruited	 by	
advertisement	at	the	University	of	Kentucky.	Acceptance	into	the	trial	will	be	based	upon	the	full	
inclusion	 and	 exclusion	 criteria	 listed	 below.	 After	 giving	 informed	 consent,	 initial	 screening	
performed	 (physical	 exam,	 blood	 analysis	 including	 HIV	 and	 Hep	 C,	 and	 urinalysis)	 and	when	
acceptability	of	the	subject	has	been	determined	they	will	be	invited	to	participate	in	the	study.	
Subjects	will	be	compensated	for	their	 time.	 	 Inclusion	and	exclusion	criteria	can	be	viewed	 in	
Appendix	E.	
The	main	objective	of	 this	phase	1	clinical	 trial	 is	 to	 test	 the	hypothesis	 that	administration	of	
trans-polydatin	 with	 D-lyxohexulose	 (D-tagatose)	 does	 not	 change	 the	 tmax	 or	 Cmax	 of	 trans-
polydatin.	All	volunteers	will	be	healthy	male	and	female	aged	18-30	years	old,	must	not	be	taking	
other	medications,	prescription	or	nonprescription,	with	no	excessive	alcohol	 intake,	and	have	
not	 previously	 participated	 in	 a	 clinical	 trial	within	 the	 last	 30	 days.	 Those	 potentially	 eligible	














8	 female)	of	which	12	participants	 (6	male,	6	 female)	will	be	used	 for	 the	actual	 study	with	4	
alternates	(2	male,	2	female)	in	case	a	participant	cannot	complete	the	study.	Six	subjects,	3	male	
and	3	female,	will	be	assigned	to	each	group.	
Each	 subject	 will	 drink	 the	 study	 drug(s)	 assigned	 to	 their	 group	 dissolved	 in	 volume	 of	
approximately	4	ounces	of	water	per	drug.	Each	drug	will	be	dissolved	separately	in	water	and	
subjects	will	drink	both	solutions	(trans-polydatin	in	the	trans-polydatin	group,	or	trans-polydatin	




















which	 12	 participants	 (6	 male,	 6	 female)	 will	 be	 used	 for	 the	 actual	 study.	 There	 will	 be	 2	








of	 t-PD	 change	 significantly	 when	 co-administered	 with	 DLH	 in	 healthy	 male	 and	 female	
volunteers.	


















M/P	 ratio	 Metabolite	 to	 Parent	 ratio	 calculated	 as:	 AUC0-8	 metabolite/AUC0-8	 parent	
pharmacokinetic	 analysis	 will	 be	 performed	 using	 WinNonlin	 Professional	 Edition	 (Pharsight	
Corporation,	 Version	 5.2).	 Nominal	 doses	 and	 sampling	 times	 will	 be	 used.	 Dose	 normalized	
parameters,	 ratios,	 and	descriptive	 statistics	will	 be	 calculated	using	WinNonlin	and	Microsoft	
Excel	(Version	11.0).	Concentration	values	found	below	the	lower	limit	of	quantification	(<	20.0	









a	 pharmaceutical,	 all	 prior	 to	 obtaining	 an	 IND	 designation	 with	 the	 FDA.	 	 Our	 lab	 was	
commissioned	to	navigate	the	acquisition	of	the	IND	for	D-tagatose	and	orchestrate	the	execution	






as	 a	 full	 2-year	 cardiotoxicity	 study	 due	 to	 negative	 outcomes	 in	 some	 already	 approved	






studies	 showing	 them	 to	 have	 activity	 in	 lowering	 markers	 of	 atherosclerotic	 development	
including	 increased	 blood	 levels	 of	 LDL,	 total	 cholesterol,	 and	 triglycerides	 as	 well	 as	
hyperglycemia.	 	 This	 was	 desirable	 due	 to	 studies	 showing	 that	 increased	 consumption	 of	
carbohydrates	leads	to	greater	dyslipidemia	than	energy	matched	diets	with	increased	free	fatty	
acids.43		As	cardiovascular	disease	is	the	primary	cause	of	mortality	in	diabetics,	this	was	a	concern	
for	 the	 patient	 population	 that	 D-tagatose	 was	 intended	 to	 treat.	 	 In	 fact,	 Police	 et	 al.	
demonstrated	 in	LDLr-/-	mice	 that	D-tagatose	administration	could	produce	dyslipidemia	when	





of	 the	 other	molecule	 towards	 reductions	 in	markers	 of	 dyslipidemia.45	 	 This	 allowed	 for	 the	
development	of	predictive	algorithms	that	aided	us	in	tweaking	the	doses	of	each	of	the	molecules	
to	 get	 the	 maximum	 affects.	 	 Administration	 of	 BSN272	 led	 to	 significant	 prevention	 of	 diet	
induced	elevations	in	LDL	and	VLDL	as	well	as	weight	gain	and	the	development	of	atherosclerosis.		
Triglycerides	 were	 also	 lower	 in	 the	 treatment	 groups	 throughout	 the	 course	 of	 the	 study	
although	it	did	not	reach	significance.45		A	follow-up	study	confirmed	the	predictive	ability	of	the	













given	 BSN272	 showed	 lower	 triglycerides	 at	 the	 end	 of	 the	 study	 then	 could	 be	 expected	 by	
combining	 the	 results	 of	 each	 as	monotherapy,	 and	 the	 results	were	 even	 below	 that	 of	 the	
normal	diet	group.111	 	The	culmination	of	these	non-obvious	findings	was	 in	the	awarding	of	a	
patent	for	BSN272.	







candidate.	 	We	 identified	Prader-Willi	Syndrome	as	a	potential	orphan	disease	 to	 target	as	no	
treatments	are	available	aimed	at	treating	the	underlying	cause	of	this	disease	which	begins	as	
inability	 to	obtain	satiety	and	eventually	develops	 into	T2DM	at	a	very	young	age.	 	The	future	
tasks	and	directions	for	this	work	are	presented	in	section	5.6	below.	
5.6	Future	Work	







that	they	express.	 	The	 informed	consent	for	volunteers	 in	the	study	has	already	been	written	






underway	 in	 our	 lab	 of	 a	 mouse	 model	 of	 Prader-Willi	 syndrome	 using	 D-tagatose	 as	
monotherapy.		A	pediatric	study	is	also	being	sought	as	the	safety	profile	of	D-tagatose	makes	it	
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The	 primary	 objectives	 of	 this	 study	 were	 to	 evaluate	 the	 treatment	 effect	 of	 D-tagatose	 on	
glycemic	control,	determined	by	a	statistically	significant	decrease	 in	hemoglobin	A1c	(HbA1c),	
and	safety	profile	of	D-tagatose	compared	to	placebo.	The	secondary	objectives	were	to	evaluate	
the	 treatment	effects	on	 fasting	blood	glucose,	 insulin,	 lipid	profiles,	 changes	 in	BMI,	 and	 the	
proportion	of	subjects	achieving	HbA1c	targets	of	<7%.	Type	2	diabetic	patients	not	taking	any	
blood	 glucose	 lowering	medications	were	 administered	 either	 15	 g	 of	D-tagatose	 dissolved	 in	
125–250	ml	of	water	three	times	a	day	or	placebo	with	meals.	Reduction	in	HbA1c	was	statistically	






















insulin	resistance	and	progressive	 failure	of	pancreatic	β-cell	 function	 leading	to	 loss	of	 insulin	
secretion.	 These	 complications	 eventually	 lead	 to	 chronic	 hyperglycemia	 and	 associated	 long-
term	disease	complications.4	 Insulin	 resistance	does	not	progress	 in	parallel	with	 loss	of	β-cell	
function,	 but	 occurs	 first.	 Most	 type	 2	 diabetes	 patients	 who	 are	 initially	 treated	 by	 diet	








program	and,	 if	 overweight,	 control	 their	weight.	 If	 the	disease	progresses	 and	blood	 glucose	
remains	uncontrolled,	then	pharmacologic	therapy	is	initiated,	usually	with	one	or	two	oral	anti-
hyperglycemic	drugs.	Additional	medications	or	insulin	may	be	added	if	the	disease	continues	to	
progress.	Many,	 if	 not	most,	 patients	with	 type	2	 diabetes	will	 eventually	 require	 insulin	 as	 a	
primary	therapy	with	or	without	adjuvant	drug	therapy	in	order	to	control	their	blood	glucose.5	
Despite	 the	 introduction	 in	 recent	 years	 of	 new	 drugs	 for	 the	 treatment	 of	 diabetes,	 glucose	
control	in	many	patients	remains	unsatisfactory.	Metformin	remains	the	first	drug	of	choice	for	
the	 treatment	 of	 type	 2	 diabetes.	 A	 recent	 review	 that	 included	 140	 controlled	 trials	 and	 26	
observational	 studies	 comparing	diabetes	medications,	 both	 as	monotherapy	 and	 in	 two-drug	








This	 information	 illustrates	 the	 limitations	 of	 drug	 therapies	 currently	 available	 for	 the	
progression	of	diabetes.	Further,	even	with	aggressive	intervention,	it	 is	estimated	that	60%	of	
diabetics	 do	 not	 achieve	 target	 blood	 sugar	 levels	 with	 their	 current	 treatment	 regimen.5	
Moreover,	current	drugs	available	for	treatment	of	diabetes	may	result	in	unwanted	weight	gain	
(long	 and	 rapid	 acting	 Insulin,	 sulfonylureas,	 thiazolidinediones,	 repaglinide,	 nateglinide),	





that	 there	 is	a	medical	need	 for	a	drug	 that	can	slow	and/or	halt	 the	progression	of	diabetes.	
Preferably,	such	a	drug	should	exhibit	a	unique	mode	of	action	to	enable	additive	or	synergistic	
use	 with	 current	 therapies;	 produce	 no	 weight	 gain,	 hypoglycemia,	 or	 other	 limiting	 or	
unmanageable	side	effects;	preserve	or	enhance	β-cell	function;	and	reduce	cardiovascular	risk	
factors	that	potentially	lead	to	morbidity	and	mortality.	
D-tagatose	 is	 an	 isomer	of	 fructose	 that	 is	~90%	as	 sweet	as	 sucrose.	 In	2001	D-tagatose	was	
designated	as	a	Generally	Recognized	as	Safe	(GRAS)	product	by	the	United	States	Food	and	Drug	
Administration,	 and	 subsequently	 has	 been	 used	 as	 a	 nutritive	 or	 low-calorie	 sweetener.10	
Currently,	D-tagatose	may	be	used	as	a	sweetener	in	diet	beverages,	light	ice	creams	or	yogurts,	
and	 regular	or	dietetic	hard	candies.11	 Subsequently	 it	was	hypothesized	 from	observations	 in	
food	use,	and	then	demonstrated	experimentally	that,	when	consumed,	D-tagatose	functions	as	
a	 “sugar	 blocker”	 and	 inhibits	 lipid	 formation	 from	 carbohydrates	 without	 stimulation	 of	
pancreatic	 beta	 cells	 for	 insulin	 production	 or	 secretion.12	 Preliminary	 animal	 and	 pre-clinical	
studies	of	D-tagatose	demonstrated	its	ability	to	lower	blood	glucose	and	lipoprotein	levels.	D-
tagatose	 has	 been	 shown	 to	 reduce	 total	 cholesterol	 and	 VLDL	 and	 LDL-cholesterol	 when	







tagatose	 are	 gastrointestinal	 disturbances	 attributed	 to	 osmotic	 effects	 from	 incomplete	
absorption.14–18	Such	effects	are	also	commonly	associated	with	excessive	consumption	of	other	




significant	 reductions	 in	hemoglobin	A1c	 levels	 (HbA1c)	 in	patients	with	mild	 type	2	diabetes.	














governing	 clinical	 trials	 including	 the	 US	 Code	 of	 Federal	 Regulations	 (CFR),	 Title	 21,	 Part	 50;	
regulations	governing	IRBs,	Title	21,	Part	56;	and	the	Declaration	of	Helsinki	concerning	medical	
research	 in	 humans	 (Recommendations	 Guiding	 Physicians	 in	 Biomedical	 Research	 Involving	
Human	Patients:	adopted	by	the	18th	World	Medical	Assembly	 (WMA),	Helsinki,	Finland,	 June	
1964	and	amended	by	the	29th	WMA,	Tokyo,	Japan,	October	1975,	the	35th	WMA,	Venice,	Italy,	
October	 1983,	 the	 41st	WMA,	 Hong	 Kong,	 September	 1989,	 the	 48th	WMA,	 Somerset	West,	
Republic	of	South	Africa,	October	1996,	and	the	52nd	WMA,	Edinburgh,	Scotland,	October	2000).	
Additional	governing	regulations	included	US	CFR	Title	21,	Part	54	and	US	CFR	Title	21,	Part	312.	






level	 at	 screening	 and	 baseline	 greater	 than	 6.6%	 and	 less	 than	 9.0%;	 a	 fasting	 glucose	
concentration	less	than	240	mg/dL	(13.3	mmol/l);	a	BMI	of	less	than	or	equal	to	45	kg/m2;	and	a	
stable	 weight	 (±10%)	 for	 3	 months	 prior	 to	 entry	 into	 the	 study.	 Exclusion	 criteria	 included:	





abuse	 of	 alcohol	 or	 narcotics;	 any	 experience	 with	 hypoglycemic	 unconsciousness;	 impaired	
hepatic,	 renal	 or	 cardiac	 function;	 uncontrolled	 hypertension;	 pregnancy,	 breastfeeding,	 or	
intention	of	becoming	pregnant	or	 judged	to	be	using	 inadequate	contraception;	documented	











of	 their	 randomized	 treatment	 and	 had	 at	 least	 one	 post-treatment	 visit	 evaluating	
safety.		
Treatment	protocol		



















exercise	 under	 physician’s	 recommendation.	 In	 addition,	 subjects	 received	 their	 randomized	
study	treatment	and	detailed	instructions	about	its	use.	A	total	of	494	subjects	were	randomized	
into	 the	 study.	 Randomization	was	 stratified	 according	 to	 screening	HbA1c	 values	 (<7.5%	and	
≥7.5%)	to	achieve	a	balanced	distribution	of	subjects	across	two	arms	(treatment	and	placebo).		





and	 were	 of	 two	 types:	 (1)	 Supply	 Visits	 and	 (2)	 Supply	 and	 Procedures	 Visits.	 HbA1c	 was	
monitored	at	baseline	(Visit	2)	and	every	2	months	thereafter	as	were	the	secondary	end-point	











to	 the	 treatment	 (i.e.,	GI	effects	 reduced	 to	mild).	The	placebo	dosage	would	be	 reduced	 in	a	

















The	need	 for	 additional	 antidiabetic	medication	was	determined	by	 an	elevated	 fasting	blood	
glucose	 value	 (>240	 mg/dL)	 not	 secondary	 to	 a	 readily	 identified	 illness	 or	 pharmacological	
treatment.	 Investigators	were	 to	withdraw	 subjects	 from	 study	 treatment	 (and	 therefore	 the	















events,	 vital	 signs,	 results	 of	 physical	 exams,	 12-lead	 ECG,	 and	 clinical	 laboratory	 tests	
(hematology,	chemistry,	and	urinalysis).	
Statistical	 Methods:	 Three	 analysis	 populations	 were	 evaluated:	 (1)	 The	 Intent-to-Treat	 (ITT)	
population,	(2)	the	Per	Protocol	(PP)	population,	and	(3)	the	Safety	population.	The	ITT	population	
was	the	focus	of	the	efficacy	analyses	for	regulatory	purposes,	with	the	PP	population	being	used	







of	 subjects	with	HbA1c	 concentration	 of	 <7%,	 (7)	 insulin,	 and	 (8)	HDL.	 Analysis	 of	 continuous	
efficacy	 variables	 used	mixed-model	 repeated-measures	 analysis	 of	 covariance	 controlling	 for	






in	 the	 ITT	 population	was	 52	with	 an	 age	 range	 between	 22	 and	 74.	 The	 ITT	 population	was	














the	 active	 treatment	 group,	 i.e.,	 subjects	 who	 received	 D-	 tagatose,	 showed	 greater	 and	
statistically	significant	reductions	in	HbA1c	levels	at	all	post-baseline	visits	when	compared	to	the	
placebo	group	(Figure	1B).	The	same	mixed	model	analysis	conducted	with	the	PP	population	data	




Analysis	 of	 subgroups:	 In	 light	 of	 the	 above	 results,	 subgroup	 analyses	 were	 conducted	 to	













In	 the	 PP	 population	 the	 D-tagatose	 treatment	 for	 both	 subgroups	 demonstrated	 greater	
reductions	in	HbA1c	compared	to	placebo	(with	the	exception	at	6	months	in	the	≥	7.5%	subgroup)	
(Figure	2C	and	2D).	However,	 a	 statistically	 significant	difference	between	 the	D-tagatose	and	
80
placebo-treatment	 groups	 was	 only	 achieved	 in	 the	 <7.5%	 subgroup	 (Figure	 2C).	 Statistical	
significance	between	D-tagatose	and	placebo	groups	was	achieved	after	6	months	of	treatment	
in	subjects	with	a	baseline	HbA1c	of	<7.5%	(Figure	2C,	p-values	of	0.0497,	0.029,	and	0.0121	after	










Further	 subgroup	analyses	were	conducted	 to	compare	 the	ability	of	D-tagatose	 to	effectively	
decrease	HbA1c	in	the	United	States	(US)	population	of	subjects	versus	subjects	of	Indian	origin.	
Interestingly,	 the	 effect	 on	 lowering	 HbA1c	was	more	 pronounced	 in	 US	 compared	 to	 Indian	
subjects	(Figure	3).	A	subgroup	analysis	on	the	ITT	US	population	(Figure	3A)	showed	a	greater	









being	 noted	 at	 all	 post-baseline	 time	 points	 (Figure	 3C).	 The	 effect	 of	 D-tagatose	 in	 reducing	






0.0016,	 <0.0001,	 <0.0001,	 and	 <0.0001,	 respectively.	 (D)	 Change	 in	 HbA1c,	 Indian	 subjects,	 PP	
population.		Zero	time	points	plotted	as	means,	remaining	time	points	plotted	as	least	squares	means	±SEM.1	
Proportion	 of	 Subjects	 Achieving	 HbA1c	 <	 7%:	 The	 data	 from	 the	 ITT	 population	 with	 LOCF	
indicated	that	the	D-tagatose	group	had	a	greater	proportion	of	subjects	achieving	an	HbA1c	level	
of	 less	 than	 7%	 at	 all	 post	 baseline	 time	 points	 compared	 to	 placebo,	 with	 the	 results	 being	
statistically	 significant	 at	 post-baseline	 months	 6,	 8	 and	 10	 (Table	 2).	 Thus,	 the	 percent	 of	
responders	in	the	D-tagatose	group	was	higher	than	in	the	placebo	group	at	6	months	(38.37%	vs	
22.4%),	 8	months	 (40.7%	vs	25.68%)	 and	10	months	 (43.02%	vs	26.23%,	 respectively).	 Similar	









Secondary	 Endpoint	 Results:	 Changes	 in	 BMI,	 fasting	 blood	 glucose,	 insulin,	 blood	 lipids:	D-
tagatose	was	also	evaluated	for	 its	placebo-controlled	treatment	effects	on	BMI,	 fasting	blood	
glucose,	 insulin,	blood	 cholesterol,	 and	 triglyceride	 levels.	 There	was	no	observed	effect	of	D-
tagatose	treatment	on	changes	in	body	weight	or	BMI	(body	mass	index)	compared	to	placebo	in	
either	the	ITT	or	PP	populations.		






vs.	 an	 increase	 of	 6.6,	 Δ	 =	 6.9	 and	 p	 =	 0.0079).	 Reductions	 were	 also	 seen	 in	 PP	 population	
analyses;	however,	none	were	statistically	significant	(Figure	4B).	Regardless	of	the	statistically	
significant	difference	in	fasting	blood	glucose	between	placebo	and	D-tagatose	groups,	there	was	































The	 results	 of	 analyses	 of	 serum	 HDL	 concentrations	 in	 the	 ITT	 population	 showed	 greater	
decreases	 in	 the	 D-tagatose	 group	 than	 in	 the	 placebo	 group	 with	 the	 differences	 being	
statistically	significant	at	all	post-treatment	time	points	in	the	ITT	population	and	at	the	month	4	
time	 point	 in	 the	 PP	 population	 (Figure	 5E	 and	 5F).	 However,	 the	 mean	 HDL	 values	 always	











22	 and	 p	 =	 0.0048	 (Figure	 6A)).	 No	 statistically	 significant	 differences	 were	 seen	 in	 the	 PP	
population	analyses	(Figure	6B).	Additionally,	subgroup	analyses	for	subjects	who	had	baseline	
triglyceride	 levels	 1)	 less	 than	 200	mg/dL,	 2)	 between	 200	 and	 500	mg/dL,	 and	 3)	 above	 500	





















showed	 similar	 results	 insofar	 as	 the	 population	 receiving	 D-tagatose	 always	 showed	 greater	
decreases	 in	HbA1c	 compared	 to	 placebo.	 Additionally,	 subgroup	 analyses	were	 done	 for	 the	
primary	 end-point	 on	 different	 subgroups	 of	 subjects	 to	 see	 if	 the	 reduction	 in	 HbA1c	 is	
significantly	different	between	the	treatment	groups	in	the	different	subgroups	i.e.,	1)	subjects	












groups	 for	 the	 secondary	 end-points	 LDL,	 total	 cholesterol,	 and	 fasting	 blood	 glucose	 when	
examining	 the	 ITT	 population.	 Reductions	were	 also	 seen	 in	 PP	 population	 analyses,	 however	
87
none	were	 statistically	 significant.	 Numerous	 studies	 have	 demonstrated	 that	 increased	 total	
cholesterol	and	particularly	elevated	LDL-cholesterol	are	associated	with	amplified	 risk	 for	 the	


















previous	 studies	 in	 humans14	 and	 rodents13	 have	 demonstrated	 significant	 weight	 loss	 and	 a	
reduction	in	body	weight	gain	with	D-tagatose,	respectively.	The	mean	body	weight	of	subjects	
(both	D-tagatose	and	placebo	groups)	included	in	this	phase	3	clinical	trial	at	baseline	was	73.8	
kg,	 or	 162	 pounds;	 with	 an	 average	 BMI	 of	 28.3	 mg/m2	 (overweight	 category).	 However,	 in	
previous	studies	which	have	demonstrated	an	effect	of	D-tagatose	to	promote	weight	loss,	the	
mean	body	weight	of	all	 subjects	at	baseline	was	much	higher	 (mean	body	weight	at	baseline	











ECG	parameters,	 vital	 signs	 or	 physical	 examinations.	 Previous	 single-dose	 and	 repeated-dose	
studies	 in	 healthy	 and	diabetic	 human	 subjects	 showed	 that	 the	predominant	 adverse	 effects	
associated	 with	 consumption	 of	 high	 levels	 D-tagatose	 were	 gastrointestinal	 disturbances	
attributed	to	osmotic	effects	from	incompletely	absorbed	tagatose.14–19,22–24	At	single	doses	of	up	
to	 25	 g	 D-tagatose	 per	 meal,	 flatulence	 was	 generally	 the	 only	 side	 effect,	 with	 nausea,	
borborygmi	 (i.e.,	 rumbling	 or	 gurgling	 noises,	 colic,	 and	 laxation	 noted	 at	 higher	 doses).	 Such	
effects	 are	 also	 commonly	 associated	 with	 excessive	 consumption	 of	 other	 poorly	 digestible	
carbohydrates.		
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In	 summary,	 results	 of	 this	 phase	 3	 clinical	 trial	 demonstrate	 an	 effect	 of	 D-tagatose	 to	
significantly	decrease	HbA1c	levels	over	time	compared	to	placebo.	The	longer	subjects	remained	





• Unlike	 many	 other	 diabetes	 drugs,	 the	 longer	 a	 patient	 is	 on	 D-tagatose	 therapy	 in	
compliance	with	instructions,	the	better	the	efficacy.		
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Peripheral	 insulin	 resistance	 and	 progressive	 failure	 of	 pancreatic	 β-cell	 function	 leading	 to	
inadequate	 insulin	 secretion	 are	 the	 two	 principal	 abnormalities	 that	 characterize	 the	
pathogenesis	 of	 type	2	diabetes.2	 Early	 intervention	 at	 the	onset	of	 type	2	diabetes	 generally	
consists	of	maintaining	a	proper	diet	and	weight,	along	with	regular	exercise.	If	control	of	blood	
glucose	 deteriorates	 further,	 then	 pharmacological	 intervention	 with	 one	 or	 more	 oral	 anti-
diabetic	agents	is	required.	Unfortunately	for	many,	type	2	diabetes	will	continue	to	progress	and	
exogenous	 insulin	 treatment	 as	 primary	 therapy	 with	 oral	 anti-diabetic	 agents	 as	 adjunctive	
therapy	are	required	in	order	to	achieve	glycemic	control.	Treatment	with	insulin	is	usually	a	point	
of	no	return	for	these	patients	and	a	major	treatment	goal	is	to	prevent	progression	to	this	point.	
Despite	 all	 of	 these	 interventions	 including	 insulin	 and	 the	 introduction	of	 a	 number	of	 novel	
agents	 for	 the	treatment	of	 type	2	diabetes	 in	recent	years,	glucose	control	 for	many	remains	
unsatisfactory.	
Recently,	 a	 review	 that	 included	140	 controlled	 trials	 and	26	observational	 studies	 comparing	
diabetes	medications,	both	as	monotherapy	and	in	two-drug	combinations,	concluded	that	there	
was	not	enough	evidence	to	clearly	support	the	use	of	one	drug	or	drug	combination	over	another	










rapid	 acting	 insulin,	 sulfonylureas,	 thiazolidinediones,	 repaglinide,	 nateglinide),	 hypoglycemia	
(insulin,	 sulfonylureas),	 gastrointestinal	 distress	 (metformin,	 α-glucosidase	 inhibitor,	 amylin	
mimetics,	 bile	 acid	 sequestrant,	 bromocriptine),	 or	 more	 serious	 adverse	 events	 such	 as	
pancreatitis	 (short	 and	 long-acting	 glucagon-like	 peptide-1	 (GLP-1)	 agonists	 and	 dipeptidyl	








D-tagatose	 is	an	 isomer	of	fructose	and	 is	~90%	as	sweet	as	sucrose,	or	sugar.	D-tagatose	was	
designated	in	2001	as	a	Generally	Recognized	as	Safe	(GRAS)	product	by	the	United	States	Food	









blood	 glucose	 and	 reduce	 HbA1c	 have	 been	 conducted	 on	 healthy	 subjects	 and	 diabetic	
patients.10–15	Single-dose	and	repeated-dose	studies	in	healthy	and	diabetic	human	subjects	have	
shown	 that	 the	 predominant	 adverse	 effects	 associated	 with	 excessive	 consumption	 of	 D-
























was	 initiated.	 This	 trial	was	 conducted	 in	 accordance	with	 regulations	 governing	 clinical	 trials	
including	the	US	Code	of	Federal	Regulations	(CFR),	Title	21,	Part	50;	regulations	governing	IRBs,	
Title	 21,	 Part	 56;	 and	 the	 Declaration	 of	 Helsinki	 concerning	 medical	 research	 in	 humans.	
Additional	governing	regulations	included	US	CFR	Title	21,	Part	54	and	US	CFR	Title	21,	Part	312.	








efficacy	 evaluable	 (EE)	 population.	 The	 population	 used	 to	 analyze	 safety	 parameters	 was	
identical	to	the	ITT	population.	Analysis	of	demographic	and	baseline	for	the	ITT,	EE	and	Safety	
populations	 indicated	 no	 gross	 dissimilarities	 between	 the	 three	D-tagatose	 dose	 groups.	 The	










each	 study	 visit	 in	 fasting	 blood	 glucose	 concentrations,	 and	 plasma	 lipids	 (triglycerides,	 low	















period	 of	 standardized	 diet	 and	 exercise.	 This	 8-week	 stabilization	 period	 was	 considered	 a	
















































Subject	Registration	to	Study	 X	 	 	 	 	
Inclusion	and	Exclusion	Criteria	 X	 	 	 	 	
Informed	Consent*		 X	 	 	 	 	
Physical	Examination	 X	 X	 	 	 X	
Medical	History/Update	 X	 X	 X	 X	 X	
Record	Concomitant	Medications	 X	 X	 X	 X	 X	
Record	Adverse	Events	 	 X	 X	 X	 X	
Hematology	Panel	 X	 X	 X	 X	 X	
Chemistry	Panel†		 X	 X	 X	 X	 X	
Liver	Function	Tests‡	 X	 X	 X	 X	 X	
Lipid	Profile§		 X	 X	 X	 X	 X	
HbA1c	levels	 X	 X	 X	 X	 X	
Urinalysis	Panel	 X	 X	 X	 X	 X	
Dispense	Study	Drug	 	 X	 X	 X	 	
Dispense	diaries	 X	 X	 X	 X	 	
Compensation	 X	 X	 X	 X	 X	
Collect	empty	study	drug	
vials/packages	 	 	 X	 X	 X	















and	 all	 assessments	 conducted	 at	 Visits	 3	 and	 4	 were	 repeated.	 Additionally,	 a	 final	 physical	
examination	was	 conducted.	 Subjects	were	 instructed	 to	 return	 to	 their	primary	physician	 for	
subsequent	diabetes	care	and	follow-up.	This	visit	had	a	±	7	day	window.	The	efficacy	and	safety	
measurements	 that	were	 evaluated	 throughout	 the	 study	 are	 provided	 in	 the	 study	 schedule	
(Table	1).	
In	the	event	a	subject	was	discontinued	for	any	reason,	an	attempt	was	to	be	made	to	keep	the	













Intent-to-Treat	 (ITT)	 Population—The	 main	 efficacy	 analysis	 was	 conducted	 using	 the	 ITT	
Population.	The	ITT	population	included	all	subjects	who	had	signed	the	study	Informed	Consent	







population	 consisted	 of	 all	 randomized	 subjects	 who	 received	 at	 least	 one	 dose	 of	 study	
medication	and	had	at	least	one	post	treatment	visit	of	safety	assessment.	
Determination	of	Sample	Size	










continuous	 data,	 summaries	 included	 number	 of	 observations,	 mean,	 standard	 deviation,	




















completing	 the	 6-month	 treatment	 period.	 The	 most	 common	 reasons	 for	 withdrawal	 were	
subject	 request	 (18/161,	 11%)	 and	 subject	 lost	 to	 follow	 up	 (11/161,	 7%).	 The	 populations	
analyzed	 for	 efficacy	 endpoints	were	 the	 ITT	 population	 (145	 total;	 52	 in	 the	 2.5	 g	 treatment	
group,	46	in	the	5.0	g	treatment	group	and	47	in	the	7.5	g	treatment	group)	and	the	EE	population	
(87	total,	31	in	the	2.5	g	treatment	group,	29	in	the	5.0	g	treatment	group,	and	27	in	the	7.5	g	
treatment	 group).	 The	 population	 used	 to	 analyze	 safety	 parameters	was	 identical	 to	 the	 ITT	




Incidence	 of	 ≥	 0.5	 HbA1c	 decrease	 after	 six	 months	 of	 treatment—Treatment	 success,	 as	
measured	by	the	incidence	of	a	0.5	minimum	HbA1c	decrease	from	baseline	after	six	months	of	
treatment,	was	greatest	for	the	7.5	g	TID	dose	of	D-tagatose	in	both	the	ITT	(25%,	12/47)	and	the	

































One	Month	 8	(15.38%)	 9	(19.57%)	 4	(8.51%)	
Three	Months	 11	(21.15%)	 8	(17.39%)	 5	(10.64%)	




















One	Month	 6	(19.35%)	 7	(24.14%)	 2	(7.41%)	
Three	Months	 9	(29.03%)	 8	(27.59%)	 2	(7.41%)	










0.66%	 and	 7.6	 ±	 1.01%,	 respectively,	 for	 the	 2.5	 g	 dose	 group;	 7.4	 ±	 0.63%	 and	 7.3	 ±	 0.85%,	
respectively,	for	the	5.0	g	dose	group;	and	7.3	±	0.60%	and	7.1	±	0.75%,	respectively,	for	the	7.5	























groups,	 respectively.	 For	 the	 EE	 population,	 the	 incidences	 of	 glucose	 decreases	 were	 70%	
(19/27),	 55%	 (16/29),	 and	 42%	 (13/31),	 respectively.	 These	 data	 are	 depicted	 in	 Figure	 5.	 No	






























93.4	 mg/dL,	 respectively,	 for	 the	 2.5	 g	 dose;	 and	 179	 ±	 99.8	 mg/dL	 and	 165	 ±	 74.7	 mg/dL,	
respectively,	 for	 the	7.5	g	dose.	The	difference	between	the	treatment	groups	at	 the	3-month	
time	point	was	statistically	significant	in	the	ITT	population	(p	=	0.0296,	ANCOVA	with	baseline	as	










were	165.4	±	33.0	 lbs,	161.5	±	29.5	 lbs,	and	161.7	±	27.5	 lbs,	respectively;	and	the	mean	body	
weights	for	the	7.5	g	D-tagatose	dose	group	were	167.4	±	33.0	lbs,	165.1	±	30.5	lbs,	and	160.6	±	





































	 n	(%)	 n	(%)	 n	(%)	 n	(%)	
Received	≥	1	Dose	 55	(96.5%)	 49	(96.1%)	 51	(96.2%)	 155	(96.3%)	
Completed	Study†	 35	(61.4%)	 32	(62.7%)	 34	(64.2%)	 101	(62.7%)	










Sixty	 (60)	 randomized	 subjects	 (37.3%)	 were	 withdrawn	 before	 completing	 the	 6-month	
treatment	period.	Two	subjects,	from	each	of	the	dose	groups	were	withdrawn	prior	to	receiving	



















Subject	Request	 3	(5.3%)	 5	(9.8%)	 10	(18.9%)	 18	(11.2%)	
Lost	to	Follow-up	 3	(5.3%)	 3	(5.9%)	 5	(9.4%)	 11	(6.8%)	
AE/SAE	 5	(8.8%)	 2	(3.9%)	 1	(1.9%)	 8	(5.0%)	
Protocol	Deviation	 3	(5.3%)	 2	(3.9%)*	 2	(3.8%)	 7	(4.3%)	
Termination	by	Sponsor	 2	(3.5%)	 0	(0.0%)	 0	(0.0%)	 2	(1.2%)	
Other	 6	(10.5%)†	 7	13.7%)	 1	(1.9%)	 14	(8.7%)	
















groups	 combined	 was	 8/161	 (5.0%)	 with	 what	 appears	 to	 be	 an	 inverse	 dose-response	
relationship;	i.e.,	as	the	dosage	increased	the	incidence	of	withdrawals	due	to	AEs	decreased.	The	
highest	 incidence	of	withdrawals	due	to	AEs	was	 in	the	2.5	g	dose	group	(5/57,	8.8%)	and	the	







tagatose	was	assumed	 (based	on	previous	 trials)8	 to	be	a	minimally	effective	dose	 in	 reducing	
















7/46	 (15%),	 respectively	 and	 the	 difference	 between	 the	 three	 dosages	were	 not	 statistically	
significant.	Similar	results	for	the	lower	doses	were	observed	with	the	EE	population.	Continuous	









of	 treatment	 with	 increasing	 reduction	 at	 the	 6-month	 time	 point,	 at	 which	 time	 statistical	
significance	was	observed	 (Figure	4),	 thereby	supporting	 the	analysis	of	 the	primary	endpoint.	
Additionally,	 for	 the	 EE	 population,	 the	 incidence	 rates	 of	 subjects	 achieving	 any	 decrease	 in	
fasting	glucose	values	indicated	consistent	increases	throughout	the	treatment	period	for	the	7.5	
g	dose	group,	although	the	differences	across	the	groups	was	not	statistically	significant	at	any	








No	 statistically	 significant	 difference	 between	 treatments	 at	 any	 measured	 time	 point	 was	










and	 the	majority	was	of	 a	 gastrointestinal	 nature,	 as	 expected.	 The	 incidences	of	 all	 reported	




provide	the	greatest	efficacy	of	 the	three	tested	doses	 in	 terms	of	 incidence	rates	achieving	≥	












• D-tagatose	 at	 7.5	 g	 TID	 provided	 the	 greatest	 effect	 in	 most	 measured	 efficacy
parameters.
• Future	research	might	 investigate	the	elevation	of	mean	triglycerides	with	the	5.0	g	D-
tagatose	 dose	 group	 after	 three	 months	 of	 treatment.	 However,	 this	 elevation	 was
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In	western	countries,	 cardiovascular	disease	 is	 the	 leading	cause	of	mortality.	While	 there	are	
multiple	 factors	 that	 increase	 the	 risk	 of	 developing	 cardiovascular	 disease,	 there	 is	 evidence	
supporting	 a	 strong	 link	 between	 abnormal	 blood	 lipids	 (dyslipidemia)	 and	 increased	 risk	 for	
cardiovascular	disease.	Dyslipidemia	is	typically	characterized	by	elevated	levels	of	triglycerides	
and	low-density	lipoprotein	(LDL)	cholesterol	and	by	low	levels	of	high-density	lipoprotein	(HDL)	






glucoside	 derivative	 of	 resveratrol.	 D-tagatose,	 a	 naturally	 occurring	 epimer	 of	 fructose,	 was	
originally	developed	as	a	low-calorie	sweetener	(1.5	kcal/g	compared	to	4	kcal/g	for	sucrose)	but	
was	 found	 to	 have	 an	 antihyperglycemic	 effect	 in	 animal	 and	 in	 human	 studies	 and	 showed	
promise	as	a	treatment	for	type	2	diabetes	and	obesity.3,4	Clinical	studies	have	shown	D-tagatose	
to	be	a	potential	anti-diabetic	drug	through	its	beneficial	effects	on	postprandial	hyperglycemia	
and	 hyperinsulinemia.4	 	 In	 addition	 to	 treating	 diabetes,	 D-tagatose	may	 also	 be	 an	 effective	
treatment	 for	 obesity4–6	 and	 for	 reducing	 cardiovascular	 risks	 by	 increasing	 high-density	
lipoprotein	 (HDL)	 levels.4	 After	 over	 10	 years	 of	 animal	 and	 human	 studies,	 D-tagatose	 was	
classified	as	being	“generally	recognized	as	safe	(GRAS)”	by	the	FDA7	and	has	been	used	since	in	
food	and	beverage	products.	
Police	 et	 al.8	 found	 that	 the	 equivalent	 substitution	 of	 D-tagatose	 for	 sucrose	 as	 a	 dietary	
carbohydrate	did	not	result	 in	 the	same	extent	of	obesity,	hyperglycemia,	hyperlipidemia,	and	
atherosclerosis	 in	 LDLr-/-	 mice.	 Mice	 fed	 standard	 lab	 chow	 and	 mice	 fed	 D-tagatose	 chow	
exhibited	similar	energy	intake,	body	weights	and	blood	glucose	and	insulin	concentrations,	while	
sucrose-chow	 fed	 mice	 exhibited	 increased	 energy	 intake	 and	 became	 obese	 and	
hyperglycemic.	 	Sucrose-fed	mice	had	 increased	serum	cholesterol,	 triglyceride	concentrations	
and	atherosclerosis	compared	to	mice	fed	D-tagatose	or	a	standard	diet.	
Polydatin	 is	a	natural	substance	that	 is	a	glucoside	form	of	resveratrol.	Evidence	suggests	 that	
resveratrol,	a	naturally	occurring	polyphenol	commonly	found	in	a	variety	of	plants	and	foods,	
most	 notably	 grapes,	 can	 produce	 a	 variety	 of	 beneficial	 effects,	 including	 the	 promotion	 of	
weight	 loss,9	 anti-oxidant	 properties10	 and	 cardioprotective,11,12	 anti-inflammatory	 and	
neuroprotective	properties.13		Recently,	it	was	found	that	the	concentration	of	polydatin	in	grapes	
is	 as	much	 as	 seven	 times	 that	 of	 resveratrol14,15	 and	 is	 probably	 the	most	 abundant	 form	of	
resveratrol	 in	 nature.16	 	 Polydatin	 has	 a	 number	 of	 advantageous	 properties	 that	 increase	 its	




properties	 similar	 to	 those	 of	 resveratrol.17	 Current	 evidence	 suggests	 polydatin	 may	 inhibit	
platelet	 accumulation,	 improve	 microcirculation,	 decrease	 lipid	 peroxidation,	 and	 reduced	
neutrophil-endothelial	aggregation.18	These	proactive	factors	may	limit	the	growth	of	plaque	in	
arteries.	
There	 is	 considerable	 interest	 in	 the	 use	 of	 trans-resveratrol	 and	 its	 derivatives,	 including	













Claims	 for	 health	 benefits	 of	 polydatin	 abound.	 Studies	 almost	 too	 numerous	 to	 count	 have	
presented	 evidence	 that	 polydatin	 has	 many	 positive	 effects	 including	 anti-inflammatory,29,30	
hepatoprotective,31–34	 anti-cancer,35–38	 neuroprotective,29,39–41	 and	 cardioprotective	
activities.11,12,20,42,43	 Pharmacological	 studies	 and	 clinical	 practice	 have	 demonstrated	 that	
polydatin	 also	 has	 protective	 effects	 against	 shock,44–46	 ischemia/reperfusion	 injury,34,47	
congestive	 heart	 failure,48	 endometriosis,49	 and	 prevention	 of	 fatty	 liver	 disease	 and	 insulin	
resistance,50	 and	 that	 it	 can	 regulate	 glucose	 and	 lipid	 metabolism.51	 	 Polydatin	 has	 recently	
participated	 in	 clinical	 trials	 for	 the	 treatment	 of	 hemorrhagic	 shock	 and	 irritable	 bowel	
syndrome.30,52	
The	way	in	which	polydatin	is	able	to	have	all	of	these	activities	is	still	being	studied,	but	multiple	
mechanisms	 of	 action	 are	 evident,	 including;	 an	 antioxidant,	 free	 radical-elimination	
mechanism,53,54	activation	of	protein	kinase	C,18,55	suppression	of	NF-kappaB,56	inhibition	of	the	
activation	of	renin-angiotensin-aldosterone	system	and	decreasing	the	excretion	of	endothelin	1,	
TNF-α,	 and	 angiotensin	 II,42	 reduction	 of	 lipid	 peroxidation	 levels,10,56	 up	 regulation	 of	 the	
expression	of	hippocampal	brain-derived	neurotrophic	 factor,41	 	enhanced	 insulin	sensitivity	 in	
the	 liver	 as	 shown	 by	 improved	 insulin	 receptor	 substrate	 2	 expression	 levels	 and	 Akt	
phosphorylation,51	 	 decreasing	 the	 content	 of	 malonydialdehyde	 (MDA),40	 promoting	 the	
activities	of	total	superoxide	dismutase	(T-SOD),	catalase	(CAT)	and	glutathione	peroxidase	(GSH-
Px)	 in	 plasma,	 increasing	 the	 content	 of	 glutathione	 (GSH)	 in	 myocardial	 tissue,54	 restoring	













ratio	 of	 total	 cholesterol	 to	 HDL	 was	 reduced	 as	 well.	 In	 our	 laboratory,	 the	 combination	 of	
polydatin	and	D-tagatose	has	been	shown	to	reduce	cholesterol,	triglycerides,	and	the	extent	of	




















21-30	 (group	 3)	 and	 31-40	 (group	 4)	 were	 forced	 to	 be	 uncorrelated	 by	 principal	 axis





dose	 in	 the	 feed	of	D-tagatose	 for	groups	3	and	4	was	 increased	by	~7.1%	daily	during	 the	D-




















Group	 Test	Article	 Dose	(g/kg/dose)	 No.	of	animals	 Animal	Numbers	
1	 Water	 0	 10	 1-10
2	 Glucose	(50%)	+	Fructose	(50%)	 See	Table	4.2	 10	 11-20
3-12 Glucose	+	Fructose	+		D-tagatose	 See	Table	4.2	 10	 21-30
13-22 Glucose	+	Fructose	+	BSN272	 See	Table	4.2	 10	 31-40
Serum	Lipids	
Blood	samples	were	obtained	through	tail	cuts	every	two	weeks	throughout	the	experiment,	and	








of	 atherosclerotic	 lesions	 in	 the	 BSN272	 treated	 group	was	 determined	 by	 dividing	 the	mean	
116










Glucose	 Fructose		 D-tagatose Piceid	
































2	 11	 100	 100	 0.853	 0.853	
2	 12	 100	 100	 0.853	 0.853	
2	 13	 100	 100	 0.853	 0.853	
2	 14	 100	 100	 0.853	 0.853	
2	 15	 100	 100	 0.853	 0.853	
2	 16	 100	 100	 0.853	 0.853	
2	 17	 100	 100	 0.853	 0.853	
2	 18	 100	 100	 0.853	 0.853	
2	 19	 100	 100	 0.853	 0.853	
2	 20	 100	 100	 0.853	 0.853	
3	 21	 80.400	 62.898	 57.269	 0.686	 0.537	 0.489	
4	 22	 51.045	 50.295	 26.541	 0.435	 0.429	 0.226	
5	 23	 30.795	 56.061	 62.352	 0.263	 0.478	 0.532	
6	 24	 29.005	 73.871	 24.031	 0.247	 0.630	 0.205	
7	 25	 81.740	 30.755	 28.551	 0.697	 0.262	 0.244	
8	 26	 84.530	 53.531	 51.408	 0.721	 0.457	 0.439	
9	 27	 28.240	 100.000	 66.251	 0.241	 0.853	 0.565	
10	 28	 47.517	 59.586	 64.954	 0.405	 0.508	 0.554	
11	 29	 36.231	 80.392	 52.726	 0.309	 0.686	 0.450	
12	 30	 63.580	 64.693	 99.000	 0.542	 0.552	 0.844	
13	 31	 70.349	 98.153	 58.858	 32.229	 0.600	 0.837	 0.502	 0.048	
14	 32	 60.832	 44.416	 77.855	 65.495	 0.519	 0.379	 0.664	 0.098	
15	 33	 54.023	 38.120	 27.662	 68.525	 0.461	 0.325	 0.236	 0.103	
16	 34	 74.222	 54.630	 72.261	 59.700	 0.633	 0.466	 0.616	 0.090	
17	 35	 64.854	 26.207	 24.886	 31.961	 0.553	 0.224	 0.212	 0.048	
18	 36	 19.168	 59.020	 57.426	 95.572	 0.164	 0.503	 0.490	 0.143	
19	 37	 52.884	 75.504	 56.847	 55.287	 0.451	 0.644	 0.485	 0.083	
20	 38	 15.852	 34.153	 80.537	 15.447	 0.135	 0.291	 0.687	 0.023	
21	 39	 37.104	 70.449	 15.971	 46.317	 0.316	 0.601	 0.136	 0.069	
22	 40	 83.795	 32.432	 60.780	 62.550	 0.715	 0.277	 0.518	 0.094	
Table	was	obtained	 from	Covance	Protocol	8242054.	Gavage	 formulation/dosing	 table	 for	each	animal	 in	
each	 group.	 	 The	 water	 group	 (negative	 control)	 is	 not	 shown.	 	 Doses	 in	 the	 Glucose/Fructose	 group	
(Treatment	2,	positive	control)	are	not	orthogonalized.		Doses	in	the	Glucose/Fructose/Tagatose	treatment	
group	 and	 the	 Glucose/Fructose/BSN272	 treatment	 group	 are	 orthogonalized	 using	 principal	 axis	
transformation	so	multiple	linear	regression	of	treatment	responses	yields	coefficients	that	do	not	change	
when	one	term	(e.g.,	one	drug)	is	added	or	dropped	from	the	model.		In	MLR	modeling,	D-tagatose	lowers	
triglycerides	 by	 -3.1	 mg/dl	 per	 g/kg/dose	 of	 the	 sugar	 in	 the	 combination,	 while	 the	 polydatin	 lowers	
triglycerides	by	-372	mg/dl	per	g/kg/dose	of	the	drug	in	the	combination.			D-tagatose	lowers	cholesterol	by	



























any	 treatment	 began	 than	 mice	 in	 the	 water	 or	 Glu/Fruc	 groups.	 This	 slight	 difference	 was	
maintained	throughout	the	course	of	the	experiment.	Even	though	mice	in	the	groups	receiving	
the	D-tagatose	 during	 the	 2-week	 lead-in	 phase	 ate	 less	 (see	 Illustration	2),	 their	weight	 gain	






Day	 78,	 end	 of	 study	 result.	 	 Glucose/Fructose	 raised	 total	 serum	 cholesterol	 in	 LDLr-/-	 mice	
compared	to	control	mice.	Treatment	with	D-tagatose	or	BSN272	prevented	the	increase	due	to	
the	 glucose/fructose	 (Illustration	 5).	 End	 point	mean	 cholesterol	 was	 322	 ±	 18	mg/dl	 for	 the	

















































lesion	was	 determined	 by	 false	 color	 imaging	 (Illustration	 9).	 Lesion	 area	was	measured	 as	 a	
fraction	of	the	aortic	arch	area.	The	percent	of	atherosclerotic	lesions	in	the	BSN272	treated	group	
was	determined	by	dividing	the	mean	atherosclerotic	lesion	area	in	the	Glu/Fruc/BSN272	group	












• D-tagatose	 lowers	 triglycerides	 by	 -3.1	 mg/dl	 per	 g/kg/dose	 of	 the	 sugar	 in	 the





• D-tagatose	 lowers	 total	 cholesterol	 by	 -3.9	 mg/dl	 per	 g/kg/dose	 of	 the	 sugar	 in	 the
combination,	while	the	polydatin	lowers	total	cholesterol	by	-629	mg/dl	per	g/kg/dose	of
the	drug	in	the	combination.
Paradoxically,	 in	 some	 animal	 models,	 D-tagatose	 and	 polydatin	 alone	 can	 raise	 serum	




Unlike	 the	 LDLr-/-	 mouse,	 the	 hamster	 has	 cholesterylester	 transfer	 protein	 (CETP),	 similar	 to	
humans.		CETP	transports	cholesteryl	esters	and	triglycerides	between	the	lipoproteins.	CETP	can	




• Serum	 triglycerides	 (TG)	were	 reduced	by	almost	one-half.	However,	 there	was	also	a
reduction	 in	 TG	 in	mouse	on	water	 treatment,	making	 it	 difficult	 to	 conclude	 that	 TG
reduction	is	treatment	related	in	the	LDLr-/-	mouse.
















Serum	 triglycerides	 (TG)	were	 cut	almost	 in	half.	 LDL	and	VLDL,	but	not	HDL,	 levels	were	also	
decreased.	 Not	 surprisingly,	 aortic	 atherosclerotic	 lesions	 were	 reduced	 by	 57%,	 as	 BSN272	
reduced	the	amount	of	lipids	moving	through	the	blood.			
Castelli	 found	that	cardiac	events	peak	in	 individuals	with	LDL	levels	of	150	mg/dl.70	 	BSN272’s	
ability	 to	 suppress	 LDL	 formation	 could	 significantly	 deter	 future	 cardiac	 impairment.	 	 Castelli	
postulated	 that	 small	dense	VLDL	particles	 settle	 in	 vessels	and	participate	 in	 forming	plaque,	
while	“fluffy”	VLDLs	simply	travel	back	to	the	liver	for	excretion.70	These	dense	VLDLs	are	likely	to	




It	 is	well	documented	that	elevated	 levels	of	LDLs	can	contribute	to	 lipoprotein	retention,	and	
higher	 levels	 of	 anti-inflammatory	 markers.71	 Presently,	 statins	 are	 often	 prescribed	 as	 lipid	
lowering	therapies,	however,	in	a	study	of	over	4000	patients,	only	40%	of	patients	being	treated	
with	a	statin	drug	regimen	were	able	to	meet	target	LDL-C	levels.72	Additionally,	statins	are	mostly	
ineffective	 in	 reducing	 triglycerides.	 In	 a	 study	of	 LDLr-/-	mice	 fed	 a	 high	 cholesterol	 (1%)	 diet	
described	by	Wang	et	al,	simvastatin	dosed	at	300	mg/kg	decreased	serum	LDL	cholesterol	levels	
from	917±	80	mg/dl	in	control	mice	to	322	±	27	mg/dl	in	simvastatin	treated	mice	and	reduced	
aortic	 lesion	 area	 by	 fifteen	 percent.	However,	 the	 treatment	 had	 no	 effect	 upon	 triglyceride	
levels.		In	the	same	study,	ApoE	mice	fed	the	same	diet	and	given	the	same	dosage	of	statin,	had	
an	increase	of	27%	in	serum	cholesterol.73	 	Apolipoprotein	E,	which	transports	cholesterol	 into	











(CHD).70	 	 Various	 studies	 have	 found	 that	Omacor	 does	 significantly	 reduce	mean	 triglyceride	
concentrations,	including	the	Harris	study	(1997)	which	reported	a	45%	reduction	in	triglycerides,	
increased	HDL	cholesterol	by	13%	and	LDL	cholesterol	by	31%,	dosed	at	3.4	g	eicosapentaenoic	
acid	 (EPA)	 and	docosapentaenoic	 acid	 (DHA)	 and	18	mg	 vitamin	E	per	day.75	Additionally,	 the	
Pownall	(1999)	study	reported	a	38.9%	decrease	from	baseline	fasting	triglyceride	levels	and	an	
increase	 in	 HDLs	 of	 5.9%	 and	 an	 increase	 in	 LDLs	 of	 16.7%.76	 EPA	 and	 DHA	 inhibit	 acyl-COA,	
resulting	 in	 decreased	 triglyceride	 synthesis,	 while	 increasing	 fatty	 acid	 metabolism,	 and	
increasing	lipase	production	which	results	in	increased	triglyceride	binding.77		
Foam	cell	formation	is	one	of	the	early	steps	in	the	process	of	atherosclerosis.78	Free	metal	ions	
can	help	 to	oxidize	 the	 LDL	and	 convert	 it	 into	a	 form	 that	 can	be	 taken	up	by	macrophages.	
BSN272	seems	to	prevent	LDL	oxidation	and	may	prevent	oxidation	caused	by	macrophages	at	
the	atherosclerotic	site.			
Although	 glucose	 and	 fructose	 had	modest	 effects	 on	 serum	 lipids	 and	 body	weight	 over	 the	
course	 of	 the	 study,	 the	 levels	 of	 serum	 cholesterol	 and	 triglycerides	 in	 the	 groups	 receiving	
glucose,	 fructose,	 and	 D-tagatose,	 and	 glucose,	 fructose,	 D-tagatose,	 and	 BSN272	 were	
consistently	equal	to	or	less	than	the	levels	in	the	groups	receiving	either	water	or	glucose	and	
fructose.	Furthermore,	the	combination	of	D-tagatose	and	polydatin	appeared	to	be	more	potent	









suggest	 that	 supplementing	 high	 carbohydrate	 meals	 with	 D-tagatose	 or	 combinations	 of	 D-
tagatose	 and	 BSN272	 may	 be	 effective	 at	 reducing	 postprandial	 carbohydrate-induced	
hyperlipidemia	and	lowering	serum	cholesterol	and	triglycerides	over	time.	
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There	 is	 considerable	 interest	 in	 the	use	of	polydatin	 for	 the	 treatment	of	a	variety	of	human	
diseases.3	Polydatin	((PD)	also	known	as	trans-polydatin,	piceid,	and	3,4',5-trihydroxystilbene-3-










by	 cells	 via	 glucose	 carriers	 in	 the	 cell	 membrane	 instead	 of	 being	 passively	 transported	 like	




cardioprotective	 activities.12,29–32	 Additional	 studies	 demonstrated	 that	 polydatin	 also	 has	
protective	effects	against	shock,33–35	 ischemia/reperfusion	 injury,36,21	congestive	heart	 failure,37	




animal	 models.	 Arichi	 et	 al.	 discovered	 that	 orally	 administered	 polydatin	 (100	 mg/kg	 body	
weight)	 significantly	 lowered	 serum	 triglycerides	 by	 40%	 and	 low-density	 lipoprotein	 (LDL)-
derived	cholesterol	by	approximately	18%.	This	study	was	performed	in	rats	consuming	standard	
chow	containing	a	mixture	of	corn	oil,	10%	cholesterol,	and	1%	cholic	acid.	Although	lower	doses	




and	63%,	 respectively,	when	 compared	 to	 standard	diet.30	 In	 another	 study	using	 rabbits,	 the	
administration	of	polydatin	decreased	serum	total	cholesterol,	triglycerides,	and	LDL.29	The	ratio	
of	total	cholesterol	to	HDL	was	also	reduced.	
Insulin	 is	 a	major	 component	of	metabolic	 regulation	 through	activation	of	 the	Akt	 and	other	
metabolic	pathways.43	Hao	et	al.	recently	found	in	diabetic	rats	that	polydatin	activated	the	Akt	
signaling	 pathway,	 possibly	 by	 phosphorylation	 of	 the	 insulin	 receptor	 substrate	 (IRS),	 thus	







metabolized	 in	minutes	 to	 hours,	 and	 eliminated	 in	 24	 hr.45–47	Metabolites	 of	 trans-polydatin	
include	glucuronidated	and/or	sulfonated	trans-polydatin,	trans-resveratrol,	and	glucuronidated	
and/or	sulfonated	trans-resveratrol.	





of	 the	 Food	 and	 Drug	 Administration	 Center	 for	 Drug	 Evaluation	 and	 Research	
(CDER)/International	Conference	on	Harmonisation	(ICH)	Harmonised	Tripartite	Guidelines	ICH-
M3,	Nonclinical	Safety	Studies	for	the	conduct	of	Human	Clinical	Trials	for	Pharmaceuticals	(CDER,	
July	 1997)	 and	 S3A,	 Toxicokinetics:	 The	 Assessment	 of	 Systemic	 Exposure	 in	 Toxicity	 Studies	
(CDER,	March	1995).	
Animals	




















of	 the	 dosing	 phase.	 Formulations	 prepared	 prior	 to	 the	 day	 of	 dosing	 were	 stored	 in	 a	





































prostate,	 rectum,	 salivary	 gland	 [mandibular	 (2)],	 sciatic	 nerve,	 seminal	 vesicle,	 skin/subcutis,	
spinal	 cord	 (cervical,	 thoracic,	 and	 lumbar),	 spleen,	 sternum	 with	 bone	 marrow,	 stomach,	
jejunum,	kidney	(2),	lesions,	liver,	lung	with	large	bronchi,	lymph	node	(mandibular),	lymph	node	
(mesenteric),	mammary	gland	 (females),	 testis	 (2),	 thymus,	 thyroid	 (2	 lobes)	with	parathyroid,	
tongue,	trachea,	urinary	bladder,	uterus,	and	vaginal	tissues	(when	present)	from	each	toxicity	
animal	 were	 preserved	 in	 10%	 neutral	 buffered	 formalin,	 with	 the	 exception	 of	 the	 eyes,	
Harderian	gland,	optic	nerves,	and	testes,	which	were	collected	in	modified	Davidson’s	fixative	
and	stored	in	10%	neutral-buffered	formalin.	
For	 histopathology,	 tissues	 were	 embedded	 in	 paraffin,	 processed	 to	 slide,	 and	 stained	 with	
hematoxylin	 and	 eosin.	 All	 preserved	 tissues	 (see	 above)	 were	 examined	 for	 histopathologic	
irregularities	 from	 toxicity	 animals	 in	 the	 control	 and	 high-dose	 groups	 and	 kidney,	 liver,	 and	
macroscopic	lesions	from	all	animals	in	the	low-,	mid-,	and	mid-high	dose	groups	were	examined	





Blood	 samples	 were	 collected	 from	 toxicity	 animals	 (see	 Table	 1)	 for	 hematology,	 clinical	
chemistry,	 and	 coagulation	 via	 a	 jugular	 vein	 from	 animals	 fasted	 overnight.	 	 Samples	 were	












1	 hour	 of	 collection,	 and	 plasma	 was	 harvested.	 	 Following	 centrifugation,	 samples	 were	
processed	under	yellow	light.		Plasma	samples	were	stored	in	a	freezer,	set	to	maintain	-60	to	-
80°C,	 until	 analyzed.	 Plasma	 analysis	 for	 trans-polydatin	 (also	 known	 as	 polydatin)	 and	 trans-































were	 dose	 dependent	 (Figure	 1).	 Decreases	 were	 of	 small	 magnitude	 (≤10%	 compared	 with	











dosing	 phase	 (Table	 3).	 This	 decrease	 was	 statistically	 significant	 for	 males.	 Lower	 food	
consumption	continued	to	be	observed	for	males	and	females	for	Weeks	2	and	3	of	the	dosing	
























2	 300	 -	 -	 -	 -	 -	 -	 -	 -	
3	 600	 -	 1.6	 1.5	 2.5	 -	 2.6	 2.9	 5.0	
4	 1200	 4.3	 5.3	 5.9	 5.9	 1.4	 2.6	 3.7	 6.6	







1	 0	 -	 -	 -	 -	 -	 -	 -	 -	
2	 300	 -	 -	 -	 -	 -	 -	 -	 -	
3	 600	 2.3	 3.6	 2.2	 1.9	 1.4	 2.0	 3.0	 4.5	
4	 1200	 6.5	 3.6	 3.5	 -	 6.8	 7.9	 7.8	 5.7	





Mean	 concentration	 time	 profiles	 for	 males	 and	 females	 showed	 mean	 concentrations	 of	
polydatin	were	generally	 similar	 after	 a	 single	dose	and	multiple	doses	of	polydatin	 (Table	4).		
After	oral	administration,	polydatin	was	readily	absorbed,	with	Tmax	values	ranging	from	0.500	




















polydatin	 300	 1	 M	 2857	 1.00	 9699	 10291	 NC	 	
	 	 	 F	 3183	 0.500	 10640	 10964	 11003	 	
	 	 25	 M	 2690	 1.00	 7629	 7741	 NA	 	
	 	 	 F	 4700	 0.500	 9472	 9593	 NA	 	
trans-	 300	 1	 M	 467	 2.00	 3235	 3619	 NC	 0.352	
resveratrol	 	 	 F	 333	 2.00	 2064	 2139	 NC	 0.195	
	 	 25	 M	 302	 2.00	 2171	 2773	 NA	 0.358	















ratios	 of	 trans-resveratrol	 to	 polydatin	 (metabolite-to-parent	 ratio)	 were	 0.352	 and	 0.358	 for	
males	and	0.195	and	0.190	for	females	on	Days	1	and	25	of	the	dosing	phase,	respectively.	
Although	maximum	serum	levels	of	polydatin	were	slightly	 less	 in	males	than	 in	 females,	both	
sexes	absorbed	polydatin	with	similar	kinetics,	reaching	peak	 levels	(approximately	3.0	mg/ml)	
within	1	hr	of	dosing	(Figure	3).	Serum	trans-resveratrol	levels	were	10-fold	less	than	polydatin	






Serum	concentrations	of	 polydatin	 and	 trans-resveratrol	 after	 the	oral	 gavage	of	 0.3	 g/kg	of	 polydatin	 in	
female	 (A)	 and	male	 (B)	 rats.	 Nine	 animals	 per	 sex	 were	 used	with	 blood	 samples	 collected	 from	 three	













were	of	 small	magnitude	and	not	 considered	adverse	or	 toxicologically	 important.	 Findings	 at	
>600	mg/kg/day	included	the	following.	
• Minimally	 lower	 glucose	 in	males	 given	 >600	mg/kg/day	 and	 females	 (not	 statistically	
significant)	given	3000	mg/kg/day	
• Minimally	higher	albumin	in	males	given	>1200	mg/kg/day	








was	detected	 in	total	bilirubin,	also	a	strong	 indicator	of	drug	 induced	 liver	 injury	(DILI).	Other	























urine	 occult	 blood	 and	 presence	 of	 red	 blood	 cells	 in	 the	 urine	 of	 a	 few	 males	 given	 3000	
mg/kg/day	and	presence	of	white	blood	cells	in	the	urine	of	a	few	females	given	3000	mg/kg/day	
were	 considered	 polydatin-related	 findings	 but	 not	 adverse.	 	 The	 change	 in	 pH	 appeared	
consistently	 present	 in	 most	 animals,	 but	 the	 remaining	 urinalysis	 findings	 were	 observed	 in	
individual	animals	and	most	were	not	associated	with	correlative	microscopic	findings.	
One	female	given	3000	mg/kg/day	had	increased	severity	of	white	blood	cell	in	the	urine,	which	
correlated	 with	 marked	 chronic	 active	 pelvic	 inflammation	 observed	 microscopically	 in	 the	
kidneys	(see	Figure	6).		However,	one	male	given	1200	mg/kg/day	with	microscopic	evidence	of	
marked	acute	renal	hemorrhage	had	no	occult	blood	or	presence	of	red	blood	cells	in	the	urine.		







































Polydatin	 related	 terminal	body	weight	 changes	were	noted	 in	animals	given	3000	mg/kg/day	
compared	with	controls.		Mean	terminal	body	weight	was	10%	lower	in	males	and	8%	lower	in	
females;	 the	 change	was	 only	 significant	 in	males.	 	 Brain-to-body	weight	 and	 kidney-to-body	
weight	ratios	were	significantly	higher	in	males	given	3000	mg/kg/day,	which	were	attributed	to	
the	 lower	 terminal	 body	 weight.	 	 Absolute	 liver	 weight	 in	 males	 given	 3000	 mg/kg/day	 was	
significantly	 lower	 (12.9%)	 than	 controls;	 these	 findings	 were	 considered	 spurious	 since	 no	
microscopic	correlate	was	present.	
Absolute	and	relative	mean	spleen	and	thymus	weights	were	also	 lower	 in	males	and	 females	




































In	 this	 study,	 administration	of	 polydatin	up	 to	3000	mg/kg/day	did	not	 result	 in	 any	 adverse	






Reduction	 in	 lymphocytes	 appears	 to	 be	 systemic	 and	 likely	 related	 to	 stress.	 One	 cortisol	
treatment	 has	 been	 shown	 to	 reduce	 lymphocytes	 by	 as	 much	 as	 70%	 in	 humans.69	 Other	
occurrences	 in	 the	 study	which	 could	 be	 interpreted	 as	 stress-related	 include	 changes	 in	 the	
spleen	 cellularity	 and	 lymph	node	 cellularity	 in	males,	 and	 increases	 in	 circulating	neutrophils	
compared	to	control	(although	not	significant).70	
Other	test	related	findings	included	minimally	higher	ALT	in	females	dosed	at	≥600	mg/kg/day	but	




Urinary	 related	 findings	 included	dilated	 tubules,	 presence	of	 hyaline	droplets,	 dilation	of	 the	
renal	 pelvis,	 inflammation	 of	 the	 pelvis,	 and	 hyperplasia	 and	 or	 ulceration	 of	 the	 transitional	












All	 animals	 survived	 to	 the	 end	 of	 the	 study.	 No	 polydatin-related	 clinical	 observations	 or	
ophthalmic	findings	were	noted.	No	marked	sex	differences	were	observed	in	polydatin	Cmax	and	
AUC0-24	 values.	 	 No	 accumulation	 of	 polydatin	 was	 observed	 after	 multiple	 dosing.	 The	 only	
adverse	test	article-related	finding	noted	in	one	female	given	3000	mg/kg/day	was	chronic	active	
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The	 primary	 objective	 of	 this	 phase	 1	 exploratory,	 microdose	 study	 is	 to	 determine	





0.167	 (10	 min),	 0.333	 (20	 min),	 0.5,	 1,	 2,	 4,	 6,	 8,	 12	 and	 24-36	 hours	 post	 drug	
administration.	Urine	 samples	will	 also	 be	 collected	 during	 the	 12	 hour	 onsite	 clinical	
period,	with	one	subsequent	sample	collected	at	visit	3,	which	should	approximate	the	
24	 hour	 post-treatment	 period.	 Serum	 and	 urine	 samples	 will	 be	 assayed	 for	 trans-






2006;	 Stevenson,	 et	 al.,	 2007).	 In	 one	 study	 using	 the	 demographic	 data	 on	 178	
deceased	individuals	with	PWS,	the	median	and	average	age	at	death	was	27	years	and	
>25%	of	 individuals	were	<19	 years	 (Stevenson,	 et	 al.,	 2007).	 In	 a	 second	 study	of	 36	
adults	with	PWS	 in	Australia,	 there	were	10	deaths	at	a	mean	age	of	33	years	 (Smith,	
2003).	 PWS	 is	 the	 most	 commonly	 known	 genetic	 cause	 of	 life-threatening	 obesity.	
Estimates	of	the	prevalence	of	PWS	range	between	1	in	12,000	to	1	in	52,000,	with	the	
most	 likely	 figure	 being	 1:15,000	 (Burd,	 et	 al.,	 1990;	 Whittington	 et	 al.,	 2001:	
www.pwsausa.org).	One	of	the	characteristics	of	PWS	is	an	insatiable	appetite	resulting	
in	obesity.	Obesity	 is	associated	with	an	 increased	risk	 for	diabetes	and	cardiovascular	
disease	and	markers	 for	 these	obesity	 related	diseases,	 such	as	 insulin	 resistance	and	
dyslipidemia,	are	commonly	exhibited	by	patients	with	PWS.	 	Because	of	 the	complex	
nature	 of	 PWS,	 and	 the	multiple	 symptoms	 exhibited	 by	 patients	 with	 PWS,	 there	 is	
currently	 no	 single	 drug	 available	 that	 can	 successfully	 treat	 all	 of	 the	 symptoms.	 For	
example,	 growth	hormone	 can	 increase	 stature	 and	muscle	 tone,	 but	 does	 not	 affect	
hyperphagia.		D-lyxo-hexulose	(DLH,	also	known	as	D-tagatose)	has	been	shown	in	both	













other	 (Lodder	 et	 al	 2015).	 	 This	makes	 BSN272,	 the	 combination	 of	 D-lyxo-hexulose	





has	 been	 implicated	 in	many	manifestations	 of	 this	 syndrome	 including	 hyperphagia,	
temperature	 instability,	 high	 pain	 threshold,	 sleep	 disordered	 breathing,	 and	multiple	
endocrine	 abnormalities.	 These	 endocrine	 abnormalities	 include	 growth	 hormone	
deficiency	 with	 resulting	 short	 stature,	 central	 adrenal	 insufficiency,	 hypogonadism,	
hypothyroidism,	 central	 obesity	 and	 complications	 of	 obesity	 such	 as	 type	 2	 diabetes	
mellitus	 (Emerick	 and	Vogt,	 2013).	Multiple	 studies	have	 indicated	high	prevalence	of	
central	adrenal	insufficiency	(CAI)	(Corrias	et	al.,	2012)	and	CAI	as	the	apparent	cause	of	






physiological	 and	 overwhelming;	 it	 is	 difficult	 to	 control	 and	 requires	 constant	
vigilance.	 Weight	 control	 depends	 on	 food	 restriction	 and	 daily	 exercise.	 Currently	
there	 is	 no	medication	or	 surgical	 intervention	 that	 can	eliminate	 the	need	 for	 strict	
dieting	and	supervision	around	food.	Studies	have	repeatedly	shown	that	PWS	patients	
are	at	risk	of	premature	death.	Mortality	in	children	is	most	commonly	associated	with	
respiratory	 infection	 and	 high	 temperature	 resulting	 in	 sudden	 death.	 Common	 in	
adults	 with	 PWS	 are	 obesity-related	 problems	 such	 as	 respiratory	 failure	 and	





A	 high	 incidence	 of	 alterations	 in	 glucose	 metabolism	 including	 impaired	 fasting	





Obesity	 and	 diabetes	 are	 well-established	 risk	 factors	 for	 premature	 cardiovascular	
disease.	A	limited	number	of	studies	have	looked	at	cardiovascular	fitness	and	disease	
markers	in	PWS	patients.	Cardiovascular	risk	factors	are	evident	in	a	large	percentage	
of	 children	 with	 PWS.	 de	 Lind	 van	 Wijngaarden	 et	 al.	 (2010)	 looked	 at	 the	
cardiovascular	 and	 metabolic	 risk	 profile	 in	 85	 children	 with	 Prader-Willi	 syndrome	








least	 one	 of	 the	 following	 factors	 was	 present:	 elevated	 systolic	 or	 diastolic	 blood	
pressure;	 elevated	 serum	 total	 cholesterol,	 low	 density	 lipoprotein	 cholesterol,	
triglycerides,	 or	 lipoprotein(a)	 levels;	 or	 reduced	 high	 density	 lipoprotein	 cholesterol	
levels	in	addition	to	a	high	fat%,	indicating	an	unfavorable	cardiovascular	profile.	Patel,	
et	al.	(2007)	assessed	cardiac	and	vascular	structure	and	function	in	nine	PWS	patients	
and	 found	 significantly	 elevated	 high-sensitivity	 C-reactive	 protein	 (hs-CRP),	 (hs-CRP	
has	 been	 shown	 to	 be	 significantly	 elevated	 in	 patients	 dying	 suddenly	 with	 severe	
coronary	 artery	 disease	 (Burke,	 et	 al.,	 2002)),	 and	 evidence	 of	 microcirculatory	
dysfunction	 as	 evidenced	 by	 decreased	 peak	 hyperaemic	 flow	 response.	 	 In	 a	 small	







obesity.	 Obesity	 is	 associated	with	 an	 increased	 risk	 for	 diabetes	 and	 cardiovascular	
disease,	and	markers	for	these	obesity	related	diseases	are	exhibited	by	patients	with	







































































































































































































































































































































































































on	 conditions	 that	 are	 commonly	 encountered	 by	 patients	 with	 PWS.	 Many	 of	 the	
problems	 faced	 by	 those	 afflicted	 with	 PWS	 stems	 from	 their	 struggle	 with	 obesity.	
Obesity	is	associated	with	an	increased	risk	for	diabetes	and	cardiovascular	disease,	and	
markers	for	these	obesity	related	diseases	are	exhibited	by	patients	with	PWS.	Multiple	
trans-polydatin	 studies	 indicate	 positive	 results	 in	 the	 following	 areas	 likely	 to	 impact	













































































































































































































































































































































































































































































































combat	 below	 normal	 values	 of	 endogenous	 GH	 experienced	 by	 most	 patients	 with	
PWS.		This	has	led	to	improvements	in	the	health	of	children	with	regards	to	growth	rate	










et	 al	 2012).	 Analysis	 was	 performed	 to	 address	 concerns	 about	 the	 use	 of	 growth	
hormone	 therapy	 in	obese	patients	due	 to	 the	anti-insulin	effects	of	growth	hormone	
and	in	patients	with	underlying	respiratory	impairment,	both	of	which	are	very	common	
phenotypes	in	PWS,	among	other	concerns.	 	Across	all	studies	notable	outcomes	were	
an	 increase	 in	 fasting	 plasma	 glucose,	 increases	 in	 fasting	 insulin	 and	 HOMA	 values	
trending	 towards	 significance,	 and	 around	 15%	of	 all	 participants	 experienced	 edema	
(Sanchez-Ortiga	et	al	2012).	One	study	even	showed	an	increase	in	left	ventricular	mass	
for	61%	of	 its	participants	and	a	mild	decrease	 in	 left	ventricle	ejection	fraction	(LVEF)	











Somatropin	 has	 been	 associated	 with	 tumor	 promoting	 potential.	 	 The	 French	 Sante	












as	 75%	 (Laurier	 et	 al.	 2014).	 	 An	observational	 study	of	 norditropin	with	 	 thirty-three	
PWS	 	 patients,	 listed	 scoliosis	 as	 an	 adverse	 event	 in	 19.5%	 of	 the	 population	
(Meinhardt	 et	 al.	 2013).	 In	 an	 additional	 study	 of	 GH	 treatment,	 	 scoliotic	 conditions	
worsened	 in	 six	 of	 the	 thirteen	 PWS	 patients	 with	 scoliosis	 (Murakami	 et	 al.	 2012).	
Colmenares	et	al.	 (2011)	 found	scoliosis	present	 in	27.8%	of	PWS	children	at	baseline,	
and	a	scoliosis	 rate	of	47.2%	three	years	 later	 in	a	prospective	cohort	study;	whereas,	
other	 studies	 have	 found	 little	 statistical	 difference	 in	 the	 rate	 of	 scoliosis	 between	





and	 elevated	 lipid	 levels	 have	 been	 reported	 in	 patients.	 	 In	 the	 treatment	 of	
hyperlipidemia,	 along	 with	 diet,	 there	 are	 numerous	 available	medications	 to	 reduce	
blood	 lipid	 concentrations.	 Statins	 (pravastatin,	 rosuvastatin,	 atorvastatin,	 and	
simvastatin)	 are	 the	 most	 commonly	 prescribed,	 which	 act	 by	 inhibiting	 cholesterol	
production	in	the	liver.	Most	circulating	cholesterol	comes	from	liver	production,	rather	
than	 diet.	 	 In	 addition,	 inhibition	 of	 cholesterol	 production	 in	 the	 liver	 stimulates	 the	
increased	uptake	of	 cholesterol	 from	 the	blood	 into	 the	 liver,	 further	 reducing	 serum	
cholesterol.	 Bile	 acid	 resins	 (cholestyramine,	 colestipol	 and	 colesevalem)	 exert	 their	
effects	by	binding	bile	acids	present	in	the	large	intestine	preventing	the	reabsorption	of	
the	 bile	 acids	 and	 the	 absorption	 of	 dietary	 cholesterol.	 Prevention	 of	 bile	 acid	
reabsorption	results	in	an	increased	production	of	bile	acids	in	liver	via	the	cytochrome	
P450-mediated	 oxidation	 of	 cholesterol	 drawn	 from	 the	 blood	 reducing	 serum	
cholesterol.	 Ezetimibe	 (Zetia	 or	 Ezetrol)	 localizes	 at	 the	 brush	 border	 of	 the	 small	
intestine,	 and	 functions	 by	 inhibiting	 cholesterol	 absorption	 from	 the	 intestine.	
Proprotein	 convertase	 subtilisin/kexin	 type	 9	 (PCSK9)	 is	 secreted	 by	 hepatocytes	 and	
binds	 to	 LDL	 receptors	 to	 mediate	 their	 uptake	 into	 hepatocytes	 and	 subsequent	



































































































D-lyxo-hexulose,	 a	 ketohexose,	offers	advantages	 to	other	 sugars	 such	as	 sucrose	and	







non-cariogenic	 properties	 (Bertelsen	 1999).	 Structurally,	 D-lyxo-hexulose	 and	 fructose	
are	highly	similar	except	 for	an	 inversion	at	C-4	 in	the	optically	active	center	 (Normen	
2001).	Although	only	having	this	small	structural	alteration,	D-lyxo-hexulose	has	greatly	
reduced	absorption	in	comparison	to	fructose.	Studies	in	both	pigs	and	rats	have	shown	
that	 only	 20-25%	 of	 ingested	 D-lyxo-hexulose	 is	 absorbed	 by	 the	 small	 intestine.	 The	
remaining	 D-lyxo-hexulose	 is	 fermented	 by	 the	microbiota	 in	 the	 large	 intestine	 into	
short	 chain	 fatty	 acids	 and	 gaseous	 products	 (CO2,	methane,	 and	 hydrogen)	 (Saunder	
1999;	 Laerke	 1999).	 The	 absorption	 process	 of	 D-lyxo-hexulose,	 unlike	 the	 carrier	




Once	 absorbed,	 D-lyxo-hexulose	 metabolism	 occurs	 in	 the	 liver	 using	 the	 identical	
biochemical	 pathway	 as	 fructose.	 Initially	 D-lyxo-hexulose	 is	 phosphorylated	 by	
fructokinase	 to	 tagatose-1-phosphate,	 which	 is	 further	 split	 by	 aldolase	 B	 to	 yield	 D-
glyceraldehyde	(GA)	and	dihydroxyacetone	phosphate	(DHAP).		Aldolase	B	acts	on	both	
fructose-1-phosphate	 and	 tagatose-1-phosphate,	 although	 the	 cleavage	of	 tagatose-1-
phosphate	occurs	at	only	about	half	the	rate	of	that	of	fructose-1-phosphate	(Rognstad	
1982).	 Like	 fructose-1-phosphate,	 the	 increase	 of	 tagatose-1-phosphate	 concentration	
stimulates	glucokinase	activity	(Agius	1994;	Van	Schaftingen	and	Vandercammen	1989)	
leading	 to	 an	 increased	 phosphorylation	 of	 glucose	 to	 glucose-6-phosphate,	 which	
further	 activates	 glycogen	 synthase	 (Seoane	 et	 al	 1996).	 Along	 with	 fructose-1-
phosphate,	tagatose-1-phosphate	 inhibits	glycogen	phosphorylase	preventing	glycogen	
from	being	broken	down	into	glucose	subunits.	The	regulation	of	these	enzymes	enables	
the	 increase	of	glycogen	synthesis	and	 the	decrease	of	glycogen	utilization	having	 the	
overall	net	effect	of	lowering	of	serum	glucose	levels	(Gergely	1985;	Ercan-Fang	2002).		
	





and	 this	may	account	 for	 the	 lower	 total	 energy	 intake	of	 subjects	 consuming	D-lyxo-


















study	 at	 a	 dose	 of	 0.64	 g/kg/day	 in	 494	 patients	 with	 diabetes	 included	 diarrhea,	
flatulence,	and	abnormal	gastrointestinal	sounds	after	chronic	dosing.	
	
In	 the	 United	 States,	 D-lyxo-hexulose	 has	 been	 granted	 generally	 recognized	 as	 safe	
(GRAS)	 status	 under	 the	 intended	 conditions	 of	 use	 in	 foods	 (GRAS	 78)	
(http://www.accessdata.fda.gov)	 currently	 permitting	 an	 estimated	 intake	 of	 6.6	
g/person/day	 at	 the	mean,	 and	14.9	 g/person/day	 at	 the	90th	percentile.	On	 July	 23,	
2003,	 the	 Korean	 Food	 &	 Drug	 Administration	 (KFDA)	 authorized	 the	 use	 of	 D-lyxo-
hexulose	in	foods.	In	February	18,	2004,	Food	Standards	Australia	New	Zealand	(FSANZ)	
issued	 a	 favorable	 final	 assessment	 report	 permitting	 the	 use	 of	D-lyxo-hexulose	 as	 a	
novel	 food	 ingredient	 (http://www.foodstandards.gov.au).	 The	 Joint	 FAO/WHO	Expert	
Committee	on	Food	Additives	(JECFA)	evaluated	D-lyxo-hexulose	at	its	55th,	57th,	61st	
and	63rd	meetings.	At	the	63rd	meeting	in	June	2004,	JECFA	stated	there	is	no	need	to	
limit	 the	 acceptable	 daily	 intake	 (ADI)	 of	 D-lyxo-hexulose.	 JECFA	 has,	 therefore,	
established	 an	ADI	 of	 “not	 specified,”	 the	 safest	 category	 in	which	 JECFA	 can	 place	 a	
food	 ingredient.	 On	December	 14,	 2005,	 D-lyxo-hexulose	was	 formally	 approved	 as	 a	




There	appear	 to	be	multiple	mechanisms	of	action	by	which	 trans-polydatin	exerts	 its	
actions.	 Activities	 include	 an	 antioxidant,	 free	 radical-elimination	mechanism	 (Hosada	
2013,	Wang	2015),	activation	of	protein	kinase	C	(Miao	2011,	Miao	2012),	suppression	
of	 NF-kappaB	 (Fresco	 2006),	 inhibition	 of	 the	 activation	 of	 renin-angiotensin-
aldosterone	 system	 and	 decreasing	 the	 excretion	 of	 endothelin	 1,	 TNF-α,	 and	
angiotensin	 II	 (Zhang	2014),	 reduction	of	 lipid	peroxidation	 levels	 (Fabris	2008,	 Fresco	




superoxide	 dismutase	 (T-SOD),	 catalase	 (CAT)	 and	 glutathione	 peroxidase	 (GSH-Px)	 in	
plasma,	 and	 increasing	 the	 content	 of	 glutathione	 (GSH)	 in	 myocardial	 tissue	 (Wang	
2015),	 restoring	decreased	deacetylase	sirtuin1	activity	and	protein	expression	 in	 liver	
tissue	 following	 severe	 shock	 (Li	 2015)	 and	 activation	 of	 sirtuin	 (Huang	 2015,	 Zeng	
2015),	 suppressing	 oxidative	 stress-induced	 lysosomal	 instability	 and	 mitochondrial	
injury	by	increasing	the	protein	expression	of	SOD2	(Li	2015).	
	
The	 use	 of	 polydatin	 as	 a	 potential	 therapy	 for	 dyslipidemia	 has	 been	 suggested	
primarily	by	three	studies	using	animal	models	(Arichi	1982,	Du	2009,	Xing	2009).	Arichi	
et	 al	 (1982)	 discovered	 that	 orally	 administered	 polydatin	 (100	 mg/kg	 body	 weight)	
significantly	lowered	low-density	lipoprotein	(LDL)-derived	cholesterol	by	approximately	








polydatin	 (50	mg/kg	body	weight)	were	 ineffective	at	preventing	hyperlipidemia,	 they	
were	 able	 to	 prevent	 the	 accumulation	 of	 cholesterol	 and	 triglycerides	 in	 the	 liver,	
suggesting	that	lower	doses	may	also	be	effective	but	to	a	much	lesser	extent.	In	a	study	
using	Syrian	golden	hamsters,	polydatin	was	found	to	decrease	total	cholesterol	 levels	
and	 total	 triglyceride	 levels	by	47%	and	63%,	 respectively,	 compared	 to	 standard	diet	
(Du	2009).	In	another	study	using	rabbits,	the	administration	of	polydatin	decreased	the	




component	 of	metabolic	 regulation	 (Whiteman	 2002).	 Hao	 et	 al.	 recently	 found	 that	
polydatin	 activated	 the	 Akt	 signaling	 pathway	 in	 diabetic	 rats,	 possibly	 by	




atherosclerotic	 development	 (Xie	 2012).	 Additionally,	 polydatin	 is	 also	 thought	 to	
provide	protection	from	oxidative	peroxidation	which	can	result	 in	cell	damage	(Fabris	




























hexulose	 were	 gastrointestinal	 disturbances	 attributed	 to	 osmotic	 effects	 from	
incompletely	 absorbed	D-lyxo-hexulose.	At	 single	doses	of	 up	 to	25	 g	D-lyxo-hexulose	
per	meal,	 flatulence	was	 generally	 the	only	 side	effect,	with	nausea,	borborygmi	 (i.e.,	
rumbling	or	gurgling	noises	in	the	gut),	colic,	and	laxation	noted	at	higher	doses	(Donner	
et	al.,	1996,	1999,	2010;	Buemann	et	al.,	1998,	1999a	&	b,	2000b;	Lee	and	Storey,	1999;	
Saunders	 et	 al.,	 1999a).	 Such	 effects	 are	 also	 commonly	 associated	 with	 excessive	
consumption	 of	 other	 poorly	 digestible	 carbohydrates	 including	 polyols.	 Liver	
enlargement	and	elevated	uric	acid	concentration	were	two	concerns	during	the	safety	
evaluation	 of	D-lyxo-hexulose	 by	 the	GRAS	 Expert	 Panel	 in	 the	US	 (D-lyxo-hexulose	 is	
self-affirmed	as	GRAS	by	a	panel	of	 independent	experts).	Standard	 toxicity	 tests	with	
high	 levels	 of	 D-lyxo-hexulose	 (i.e.,	 diets	 of	 10	 to	 20%	 D-lyxo-hexulose)	 showed	 a	






male	 subjects	were	 studied	 in	a	double-blind	crossover	 study	with	 the	 ingestion	of	D-
lyxo-hexulose	(3	x	15	g	daily)	and	placebo	(sucrose,	3	x	15	g	daily)	for	a	period	of	28	days	
each.	 Liver	 volume	 and	 glycogen	 concentration	 were	 determined	 by	 magnetic	









metabolism.	 The	 ingestion	 of	 single	 high	 bolus	 doses	 of	 D-lyxo-hexulose	 (≥30	 g)	 is	
associated	 with	 a	 mild,	 transient	 increase	 of	 plasma	 uric	 acid	 concentration	 in	 both	
healthy	subjects	and	patients	with	type-2	diabetes	(Buemann	et	al.,	2000c;	Saunders	et	
al.,	1999a;	Diamantis	and	Bar,	2001).	However,	repeated	daily	doses	of	3	x	15	g	D-lyxo-
hexulose	 ingested	with	 the	main	meals	 for	a	period	of	28	days	produced	no	effect	on	








no	 reason	 to	 expect	 a	 postprandial	 increase	 of	 plasma	 uric	 acid	 concentrations	 in	












In	a	phase	 II	 trial	 in	which	D-lyxo-hexulose	was	administered	at	2.5	g,	5.0	g	and	7.5	g	
doses	 with	 no	 run	 in	 period,	 the	 main	 reason	 for	 failure	 to	 complete	 the	 trial	 was	
withdrawal	(37%),	subjects	asked	to	leave	or	were	lost	to	follow	up,	and	not	due	to	an	

















(AE)	 2.5	g	 5.0	g	 7.5	g	 placebo	 15	g	
Total	%	of	AE	
documented	for	




disorders	 44.20%	 34.80%	 36.2	 58.00%	 79.50%	
%	of	AE	that	
were	infections	
















on	 the	 effects	 of	 phenylethylamine	 (PEA)	 and	 trans-polydatin	 in	 patients	 with	

















study	 0	 50%	 20%	 10%	
%	of	AE	that	were	
gastrointestinal	
disorders	 	 50%	 100%	 100%	
%	of	AE	that	were	
gynecological	
disorders	 	 50%	 	 	
Cobellis	et	al	20111;	Indraccolo	et	al	20102;	Murina	et	al	20133	
	



































































15.	 Concomitant	 usage	 of	 daily	 nonsteroidal	 anti-inflammatory	 drugs	 (aspirin	 >	 325	
mg/day).	
16.	Oral	corticosteroids	(prednisone	and	prednisolone).	
17.	 Anticholinergics.	 ((Benztropine	 (Cogentin),	 Ipratropium	 (Atrovent),	 Oxitropium	








23.	 Any	 behavioral	 or	 social	 problems	 that	 may	 interfere	 with	 the	 clinical	 study	
procedures.	
24.	Patient	is	unlikely,	in	the	investigator's	opinion,	to	complete	the	study	
25.	 Have	 consumed	 grapes,	 grape-containing	 products,	 peanuts,	 peanut-containing	
products,	 blueberries,	 blueberry-containing	 products,	 chocolate,	 and	 chocolate-














of	 subjects	 should	be	avoided.	Should	a	subject	decide	 to	withdraw,	all	efforts	will	be	
made	 to	 complete	 and	 report	 the	 observations	 as	 thoroughly	 as	 possible	 and	 collect	
study	 products.	 If	 a	 subject	 withdraws	 from	 the	 study	 due	 to	 an	 adverse	 event,	 the	





trial	 related	 activities	 are	 undertaken.	 The	 consent	 form	 will	 outline	 all	 study	















The	 main	 objective	 of	 this	 phase	 1	 clinical	 trial	 is	 to	 test	 the	 hypothesis	 that	
administration	of	trans-polydatin	with	D-lyxo-hexulose	does	not	change	the	tmax	or	cmax	
of	trans-polydatin.	All	volunteers	will	be	healthy	male	and	female	aged	18-30	years	old,	
must	 not	 be	 taking	 other	 medications,	 prescription	 or	 nonprescription,	 with	 no	
excessive	alcohol	intake,	and	have	not	previously	participated	in	a	clinical	trial	within	the	
last	 30	 days.	 Those	 potentially	 eligible	 subjects	 meeting	 the	 initial	 inclusion	 and	
exclusion	 requirements,	 and	 after	 signing	 informed	 consent,	 will	 undergo	 a	 basic	




duration	of	 the	 study.	 Randomization	 is	 to	 be	 stratified	 according	 to	 sex	 to	 achieve	 a	
balanced	distribution	of	subjects	across	the	2-treatment	groups.	The	treatment	groups	




the	12	hours	 the	 volunteers	 are	 at	 the	CCTS,	with	one	 subsequent	urine	 collection	at	
visit	 3,	 which	 should	 approximate	 24	 hours	 post-treatment,	 and	 will	 be	 stored	 for	





study	with	 4	 alternates	 (2	male,	 2	 female)	 in	 case	 a	 participant	 cannot	 complete	 the	
study.	Six	subjects,	3	male	and	3	female,	will	be	assigned	to	each	group.	
	
At	 the	 initial	 recruitment/screening	 a	 full	 explanation	 of	 the	 trial	 requirements	 and	
expectations	 will	 be	 given	 to	 the	 volunteers	 and	 a	 signed	 consent	 will	 be	 obtained	
before	beginning	the	screening	process.	 	Then	every	consenting	volunteer	will	provide	
medical	history,	have	their	vital	measurements	taken	(weight,	height,	and	BP),	undergo	
a	 basic	 physical	 examination,	 blood	 samples	 taken	 for	 hematology	 (hematocrit,	
hemoglobin,	 MCH,	 MCHC,	 MCV,	 total	 WBC,	 platelet	 count,	 and	 differential),	 clinical	
chemistry	(sodium,	potassium,	chloride,	CO2,	BUN,	albumin,	creatinine	clearance,	SGOT,	




















approximately	 4	 ounces	 of	 water	 per	 drug.	 Each	 drug	 will	 be	 dissolved	 separately	 in	













After	 administration	 of	 the	 study	 drugs,	 blood	 samples	 will	 then	 be	 taken	 at	
approximately	0.167	(10	mins),	0.333	(20	mins),	0.5,	1,	2,	4,	6,	8,	12	and	once	between	
24-36	hours	post	dose.	Urine	samples	will	also	be	collected	during	the	12	clinical	period,	
with	 one	 subsequent	 collection	 at	 the	 24-hour	 time	 point	 (visit	 3).	 Subjects	 will	 be	
required	to	attend	the	trial	facility	after	a	12	hours	overnight	fast.	Subjects	will	remain	in	
the	 facility,	 and	 monitored	 constantly	 for	 safety	 for	 the	 duration	 of	 the	 timed	
















The	 trial	 evaluations	 are	 illustrated	 in	 Table	 11.	 At	 visit	 1	 (screening)	 the	 volunteer’s	
medical	 history,	 medications,	 physical	 assessment,	 and	 laboratory	 evaluation	 will	 be	
performed.	 Laboratory	 tests	 include	 electrolytes	 (sodium,	 potassium,	 chloride,	 and	
bicarbonate),	renal	function	(BUN	and	creatinine),	Liver	function	(AST,	ALT,	CK)	albumin,	
alkaline	phosphatase,	total	bilirubin	and	LDH	at	baseline	and	then	at	the	end	of	the	trial.	
The	 study	 into	 the	 pharmacokinetic	 effects	 of	 increasing	 BSN272	 therapy	 will	 be	




during	 the	 trial	 and	 any	 unexpected	 or	 adverse	 effects	 recorded.	 Any	 adverse	 results	































All	materials	supplied	are	 for	use	only	 in	 this	clinical	 trial	and	will	not	be	used	for	any	
other	 purposes.	 The	 investigators	 or	 designees	 will	 maintain	 a	 full	 record	 of	 product	

















The	 study	 products	 (D-lyxo-hexulose	 and	 trans-polydatin)	 will	 be	 stored	 at	 a	






to	 screening	 and	 enrollment	 each	 volunteer	will	 be	 provided	both	 verbal	 and	written	
study	relevant	information	and	will	have	any	questions	or	concerns	they	have	answered.	
If	 the	volunteers	make	 the	decision	 to	participate	 in	 the	 trial,	 they	will	 then	complete	
and	 sign	 an	 informed	 consent	 form.	 At	 this	 point,	 based	 upon	 the	 inclusion	 and	
exclusion	criteria	the	potential	volunteer’s	medical	history	will	be	recorded,	have	initial	
blood	 samples	 taken	 and	 be	 given	 a	 basic	 physical	 exam.	 The	 basic	 physical	 exam	
includes	 physical	 measurements	 (weight,	 height	 and	 BMI),	 general	 examination	 by	
observation	 (inspection),	 blood	pressure,	 and	heart	 rate	 check.	 The	 clinical	 laboratory	
tests	 include	 (1)	 hematology	 (hematocrit,	 hemoglobin,	MCH,	MCHC,	MCV,	 total	white	
blood	 cells,	 platelets,	 and	 differential),	 and	 (2)	 clinical	 chemistry	 (sodium,	 chloride,	
potassium,	 CO2,	 BUN,	 uric	 acid,	 albumin,	 creatinine	 clearance,	 SGOT,	 ALT,	 bilirubin,	
phosphorus,	calcium,	alkaline	phosphatase,	total	protein,	and	glucose.	Also	HIV	and	Hep	
C	 screening	 will	 be	 performed.	 Urine	 analysis	 will	 also	 be	 performed	 that	 includes	
appearance,	 volume,	 specific	gravity,	pH,	glucose,	protein,	and	microscopic	evaluation	















volunteers	 will	 be	 fitted	 with	 an	 angiocath	 for	 ease	 of	 timed	 pharmacokinetic	 blood	




















will	 be	 collected	 during	 the	 12	 hours	 post-treatment	 period	 with	 a	 subsequent	 final	
urine	 sample	 to	 be	 collected	 during	 visit	 3.	 Blood	 samples	 will	 be	 collected	 in	
heparinized	 tubes	 and	 will	 be	 kept	 on	 ice	 until	 plasma	 separation	 by	 centrifugation.	
During	blood	collection	time	intervals	the	subject	will	remain	in	the	clinical	test	facility	










Potential	 subjects	will	 be	 screened	 to	 identify	 16	 study	 healthy	 volunteers	 (8	male,	 8	
female)	 of	which	12	participants	 (6	male,	 6	 female)	will	 be	used	 for	 the	 actual	 study.	
There	 will	 be	 2	 treatment	 groups	 each	 having	 6	 volunteers	 randomly	 assigned.	 The	
determination	 of	 the	 minimum	 study	 group	 numbers	 is	 based	 upon	 a	 28	 day	 rat	


























AUC0-t		 -	Area	under	 the	concentration-time	curve	 from	hour	0	 to	 the	 last	measurable	
concentration,	estimated	by	the	linear	trapezoidal	rule.	
	




Where	Ct	 is	 the	 last	measurable	 concentration	and	λz	 is	 the	elimination	 rate	 constant	
estimated	using	log-linear	regression	during	the	terminal	elimination	phase.	The	number	




M/P	 ratio	 -	Metabolite	 to	 Parent	 ratio	 calculated	 as:	 AUC0-8	metabolite/AUC0-8	 parent	
pharmacokinetic	 analysis	 will	 be	 performed	 using	 WinNonlin	 Professional	 Edition	
(Pharsight	 Corporation,	 Version	 5.2).	 Nominal	 doses	 and	 sampling	 times	will	 be	 used.	
Dose	 normalized	 parameters,	 ratios,	 and	 descriptive	 statistics	will	 be	 calculated	 using	
WinNonlin	 and	Microsoft	 Excel	 (Version	 11.0).	 Concentration	 values	 found	 below	 the	
lower	 limit	 of	 quantification	 (<	 20.0	 ng/mL	 for	 trans-polydatin	 and	 <	 10.0	 ng/mL	 for	




























Each	 batch	 of	 samples	 analyzed	 should	 include	 a	 calibration	 curve,	 a	 matrix	 blank,	 a	
control	zero	(matrix	blank	containing	internal	standard),	a	reagent	blank,	and	duplicate	
quality	 control	 (QC)	 samples	at	 three	concentrations	within	 the	calibration	 range.	The	
samples	were	interspersed	with	calibration	standards	and	QC	samples	within	the	batch.	
	
Sample	 results	 will	 be	 considered	 valid	 if	 calibration	 curve	 and	 QC	 data	 indicate	 the	
method	met	the	acceptance	criteria,	which	includes:	no	more	than	1/4	of	the	standards	











An	 AE	 is	 therefore	 any	 unfavorable	 and	 unintended	 sign	 (including	 an	 abnormal	
laboratory	finding),	symptom	or	disease	temporally	associated	with	the	administration	
of	an	investigational	product,	whether	or	not	related	to	that	investigational	product.		An	














Note:	 The	 term	 "life-threatening"	 in	 the	 definition	 of	 "serious"	 refers	 to	 an	
event	in	which	the	patient	was	at	risk	of	death	at	the	time	of	the	event;	it	does	








Medical	 and	 scientific	 judgment	 should	 be	 exercised	 in	 deciding	 whether	 expedited	
reporting	is	appropriate	in	other	situations,	such	as	important	medical	events	that	may	
not	 be	 immediately	 life-threatening	 or	 result	 in	 death	 or	 hospitalization	 but	 may	
jeopardize	 the	 patient	 or	 may	 require	 intervention	 to	 prevent	 one	 of	 the	 other	
outcomes	listed	in	the	definition	above.	These	should	also	usually	be	considered	serious.	
		
The	 Common	 Terminology	 Criteria	 for	 Adverse	 Events	 (CTCAE)	 Version	 4.0	 should	 be	
used	 to	assess	and	grade	AE	 severity,	 including	 laboratory	abnormalities	 judged	 to	be	
clinically	 significant.	 The	 modified	 criteria	 can	 be	 found	 in	 the	 study	 manual.	 	 If	 the	














*Instrumental	 ADL	 refer	 to	 preparing	 meals,	 shopping	 for	 groceries	 or	 clothes,	 using	 the	 telephone,	
managing	money,	etc.	










































The	 Sponsor-Investigator/Safety	Officer	will	 inform	 the	 IRB	of	 any	 events	 of	which	he	
becomes	aware.	
Serious	Adverse	Event	Reporting	 	






is	 evidence	 to	 suggest	 a	 causal	 relationship	 between	 the	 therapeutic	 agent	 and	 the	
adverse	event,	such	as:	
		
(A)	 	 A	 single	 occurrence	 of	 an	 event	 that	 is	 uncommon	 and	 known	 to	 be	












known	 consequences	 of	 the	 underlying	 disease	 or	 condition	 under	
investigation	 or	 other	 events	 that	 commonly	 occur	 in	 the	 study	 population	



























Incidents	 or	 events	 that	 meet	 the	 OHRP	 criteria	 for	 UPs	 require	 the	 creation	 and	
completion	of	an	UP	report	form.	It	is	the	site	investigator’s	responsibility	to	report	UPs	
to	their	IRB.	The	UP	report	will	include	the	following	information:	








To	 satisfy	 the	 requirement	 for	 prompt	 reporting,	 UPs	 will	 be	 reported	 using	 the	
following	timeline:	
● UPs	that	are	SAEs	will	be	reported	to	 the	 IRB	 	within	7	days	of	 the	 investigator	





per	 Serious	 or	 Continuing	Noncompliance	 or	Unanticipated	 Problems	 Involving	
Risks:IRB	Reporting	to	Federal	Agencies	using	the	UK	 IRB	reporting	form	within	




















by	 the	 World	 Medical	 Assemblies,	 and	 the	 ICH	 guidelines	 for	 Good	 Clinical	 Practice	
(GCP).	Those	Investigators	participating	as	leaders	in	this	trial,	including	members	of	the	
Executive	 and	 Operations	 Committees	 and	 National	 Coordinators,	 will	 receive	
compensation	 for	 their	 time	 but	 will	 receive	 no	 financial	 profit	 from	 their	 activities	
related	to	the	trial.		
Laws	and	Regulations		
This	 Clinical	 Trial	 will	 be	 conducted	 in	 compliance	 with	 all	 international	 laws	 and	
regulations,	and	national	laws	and	regulations	of	the	countries	in	which	the	clinical	trial	
is	 performed,	 as	 well	 as	 any	 applicable	 guidelines.	 The	 trial	 will	 be	 registered	 on	
www.clintrials.gov	and	on	other	sites,	as	appropriate.		
Informed	Consent		
The	 Investigator	 (according	 to	 applicable	 regulatory	 requirements),	 or	 a	 person	
designated	by	the	 Investigator,	and	under	the	 Investigator's	responsibility,	should	fully	
inform	 the	 patient	 of	 all	 pertinent	 aspects	 of	 the	 clinical	 trial,	 including	 the	 written	
information	given	approval/favorable	opinion	by	 the	 Institutional	Review	Board/Ethics	
Committee	 	Prior	 to	a	patient’s	participation	 in	 the	 clinical	 trial,	 the	written	 Informed	
Consent	Form	should	be	signed,	name	filled	in	and	personally	dated	by	the	patient	or	by	
the	patient’s	 legally	acceptable	 representative,	 and	by	 the	person	who	conducted	 the	
informed	consent	discussion.	A	copy	of	the	signed	and	dated	written	Informed	Consent	
Form	 will	 be	 provided	 to	 the	 patient.	 If	 informed	 consent	 is	 obtained	 under	 special	
circumstances	 (emergency,	 from	 a	 guardian,	 minor,	 etc.),	 the	 method	 should	 be	
specified	 following	 the	 ICH	 requirements.	 The	 first	 part	 of	 the	 section	 should	 be	
adapted,	 keeping	 the	 point	 as	 appropriate.	 The	 Informed	 Consent	 Form	 used	 by	 the	
Investigator	 for	 obtaining	 the	 patient's	 informed	 consent	 must	 be	 reviewed	 and	
approved	 by	 the	 Sponsor	 prior	 to	 submission	 to	 the	 appropriate	 IRB	 for	
approval/favorable	opinion.		
Institutional	Review	Board	(IRB)		










Protocol,	 Informed	Consent	 Form,	 Investigator’s	 Brochure,	 Investigator’s	 CV,	 etc.)	 and	
the	date	of	 the	 review	should	be	clearly	 stated	on	 the	written	 IRB	approval/favorable	




of	 any	 event	 likely	 to	 affect	 the	 safety	 of	 patients	 or	 the	 continued	 conduct	 of	 the	
Clinical	 Trial,	 in	 particular	 any	 change	 in	 safety.	 All	 updates	 to	 the	 Investigator’s	




The	 Investigator(s)	 undertake(s)	 to	 perform	 the	 Clinical	 Trial	 in	 accordance	 with	 this	
Clinical	 Trial	 Protocol,	 ICH	 guidelines	 for	 Good	 Clinical	 Practice	 and	 the	 applicable	
regulatory	 requirements.	 	 The	 Investigator	 is	 required	 to	 ensure	 compliance	 with	 all	
procedures	required	by	the	Clinical	Trial	Protocol	and	by	study	procedures	provided	by	
the	Sponsor	 (including	 security	 rules).	 The	 Investigator	agrees	 to	provide	 reliable	data	




have	 to	 be	 defined	 (e.g.,	 e-CRF,	 Fax),	 particular	 attention	 should	 be	 paid	 to	 the	
confidentiality	of	the	patient's	data	to	be	transferred.	The	Investigator	may	appoint	such	
other	 individuals	as	he/she	may	deem	appropriate	as	Sub-Investigators	to	assist	 in	the	
conduct	 of	 the	 Clinical	 Trial	 in	 accordance	 with	 the	 Clinical	 Trial	 Protocol.	 All	 Sub-
Investigators	 shall	 be	 timely	 appointed	 and	 listed.	 The	 Sub-Investigators	 will	 be	
supervised	 by	 and	 under	 the	 responsibility	 of	 the	 Investigator.	 The	 Investigator	 will	
provide	them	with	a	Clinical	Trial	Protocol	and	all	necessary	information.		
Responsibilities	of	the	Sponsor		
The	 Sponsor	 of	 this	 Clinical	 Trial	 is	 responsible	 to	 Health	 Authorities	 for	 taking	 all	
reasonable	steps	to	ensure	the	proper	conduct	of	the	Clinical	Trial	Protocol	as	regards	
ethics,	Clinical	Trial	Protocol	compliance,	 integrity	and	validity	of	the	data	recorded	on	
the	 Case	 Report	 Forms.	 Thus,	 the	 main	 duty	 of	 the	 Monitoring	 Team	 is	 to	 help	 the	
Investigator	 and	 the	 Sponsor	maintain	 a	 high	 level	 of	 ethical,	 scientific,	 technical	 and	
regulatory	 quality	 in	 all	 aspects	 of	 the	 Clinical	 Trial.	 At	 regular	 intervals	 during	 the	
Clinical	Trial,	 the	site	will	be	contacted,	through	monitoring	visits,	 letters	or	telephone	
calls,	by	a	representative	of	the	Monitoring	Team	to	review	study	progress,	Investigator	

















personnel,	 the	 Ethics	 Committee	 (IRB),	 and	 the	 regulatory	 authorities	 to	 have	 direct	
access	to	source	data	which	supports	the	data	on	the	Case	Report	Forms	(e.g.,	patient's	




It	 is	 the	 responsibility	 of	 the	 Investigator	 to	 maintain	 adequate	 and	 accurate	 CRFs	
designed	 by	 the	 Sponsor	 to	 record	 all	 observations	 and	 other	 data	 pertinent	 to	 the	
clinical	 investigation.	 All	 source	 documents	 should	 be	 completed	 in	 their	 entirety	 in	
electronic	 format	 to	 ensure	 accurate	 interpretation	 of	 data,	which	 should	 be	 entered	
within	48	hours	of	completion	or	any	modification	into	the	eCRF.	Should	a	correction	be	
made,	 the	 information	will	 be	 re-entered	with	 tracked	 changes	 that	 show	who	made	
which	changes	and	when.	The	corrected	information	will	be	entered	by	the	authorized	
person	 into	 the	 eCRF.	 The	 computerized	 handling	 of	 the	 data	 by	 the	 Sponsor	 after	
receipt	of	the	CRFs	may	generate	additional	requests	(DRF)	to	which	the	Investigator	is	






the	 study	 to	 be	 fully	 documented	 and	 the	 study	 data	 to	 be	 subsequently	 verified,	 in	





considered	 original	 documents,	 data,	 and	 records.	 This	may	 include	 hospital	 records,	











the	 clinical	 trial	 and	 stored	 in	 a	 secure	 electronic	 database.	 The	 investigator(s)	 will	











All	 data	will	 be	 entered	 into	 electronic	 CRFs	with	 tracked	 changes.	 All	 data	manually	
entered	 in	 the	 database	 will	 be	 verified	 by	 a	 double-key	 entry	 procedure.	 After	
completion	 of	 the	 entry	 process,	 computer	 logic	 checks	will	 be	 run	 to	 check	 for	 such	
items	 as	 inconsistent	 study	 dates	 and	 outlying	 laboratory	 values.	 Any	 necessary	
corrections	 will	 be	 made	 to	 the	 database	 and	 documented	 via	 tracked	 changes.	 A	
manual	 review	of	selected	 line	 listings	will	also	be	performed	at	 the	end	of	 the	study.	










The	 investigator	 will	 assure	 that	 subjects’	 anonymity	 will	 be	 maintained.	 On	 CRFs	 or	
other	documents	submitted	to	CRO,	subjects	will	not	be	identified	by	their	names,	but	
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